Thermal Therapy and Blood Pressure: Mechanisms of Hypertension Management Through Heat and Cold

1. Introduction: Thermal Stress as an Antihypertensive Intervention

Hypertension, defined as a sustained resting blood pressure at or above 130/80 mmHg by the 2017 American College of Cardiology/American Heart Association guidelines (or 140/90 mmHg by older criteria still used in some countries), affects approximately 1.28 billion adults worldwide, according to a 2021 analysis published in The Lancet. It remains the leading modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease globally. Despite the availability of effective pharmacological treatments and well-established lifestyle interventions including sodium restriction, weight loss, and aerobic exercise, blood pressure control rates in most countries remain below 50 percent of diagnosed hypertensive individuals. The gap between hypertension prevalence and adequate management represents one of the most significant public health challenges in cardiovascular medicine.

Against this backdrop, interest in thermal therapy as an adjunct antihypertensive intervention has grown substantially over the past decade, driven in part by large observational studies from Finland documenting inverse relationships between sauna frequency and cardiovascular mortality, and in part by growing scientific interest in the mechanisms by which both heat and cold stress modulate vascular function. The term "thermal therapy" in this context encompasses heat-based interventions including traditional Finnish dry sauna, infrared sauna, and heated baths, as well as cold-based interventions including cold water immersion and cold shower exposure, and combined protocols involving alternating heat and cold (contrast therapy).

The appeal of thermal therapy as a blood pressure management strategy stems from several factors. Thermal interventions are generally accessible, low-cost (particularly cold water immersion), non-pharmacological, and associated with additional health benefits beyond blood pressure reduction, including improved subjective wellbeing, reduced muscle soreness, enhanced endothelial function, and potential reductions in inflammatory markers. For patients who are unable to exercise vigorously due to osteoarthritis, heart failure, or other limiting conditions, passive heat therapy offers a means of generating a physiological stimulus with cardiovascular effects that partially overlap with those of aerobic exercise.

This review evaluates the complete current evidence base for thermal therapy as a blood pressure intervention. It addresses the physiological mechanisms by which heat and cold independently modulate vascular resistance and blood pressure, the clinical trial and population study data supporting antihypertensive effects, the specific role of the renin-angiotensin-aldosterone system and nitric oxide pathways, the evidence for and against contrast therapy, direct comparisons with aerobic exercise, safety considerations particularly relevant to hypertensive patients, and a practical evidence-based protocol. The review maintains a rigorous distinction between what randomized trials demonstrate, what observational data suggests, and what the mechanistic evidence plausibly explains but has not yet been demonstrated in human trials.

Practitioners interested in implementing thermal therapy protocols for cardiovascular benefit can explore temperature-controlled systems designed for systematic heat and cold exposure at sweatdecks.com/cardiovascular.

2. Blood Pressure Physiology: Systemic Vascular Resistance and Cardiac Output

Understanding how thermal therapy modulates blood pressure requires a firm grounding in the determinants of arterial blood pressure. Mean arterial pressure (MAP) is the product of cardiac output (CO) and systemic vascular resistance (SVR): MAP = CO x SVR. Cardiac output itself is the product of heart rate and stroke volume. Any intervention that reduces SVR, reduces cardiac output, or reduces both will lower blood pressure; conversely, any intervention that increases either parameter will raise it.

Systemic Vascular Resistance

SVR is the primary target of most antihypertensive drugs and the primary mechanism through which thermal interventions exert their blood pressure effects. SVR is determined by the tone of resistance arterioles throughout the body, particularly in the peripheral circulation. Arteriolar tone is regulated by multiple systems operating on different timescales: the autonomic nervous system (acting within seconds to minutes through adrenergic receptors), circulating hormones including angiotensin II and norepinephrine (acting within minutes to hours), locally produced vasodilators including nitric oxide and prostacyclin (acting locally within seconds), and long-term structural changes in vessel wall thickness and composition.

Heat stress reduces SVR through vasodilation, primarily in cutaneous vessels where heat dissipation occurs. Cold stress increases SVR through vasoconstriction, particularly in peripheral vessels where heat conservation is prioritized. The divergent acute effects of heat and cold on SVR mean that their acute effects on blood pressure point in opposite directions, even as chronic exposure to either may produce sustained reductions in resting blood pressure through shared adaptive mechanisms involving nitric oxide, the RAAS, and vascular remodeling.

The Renin-Angiotensin-Aldosterone System

The renin-angiotensin-aldosterone system (RAAS) is the most powerful long-term regulator of blood pressure in mammals. Renin, secreted by juxtaglomerular cells in the kidney in response to reduced renal perfusion pressure, sodium depletion, or sympathetic stimulation, cleaves angiotensinogen to angiotensin I. Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II, which raises blood pressure through multiple mechanisms: direct vasoconstriction via AT1 receptors on smooth muscle cells, stimulation of aldosterone secretion from the adrenal cortex leading to sodium and water retention, central nervous system effects increasing sympathetic tone, and stimulation of thirst. RAAS inhibition is the basis of ACE inhibitors and angiotensin receptor blockers (ARBs), two of the most commonly prescribed classes of antihypertensive drugs globally.

Endothelial Function and Blood Pressure

The vascular endothelium, the monolayer of cells lining the interior of all blood vessels, plays a central role in blood pressure regulation through the production and release of vasoactive molecules. Endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO) in response to shear stress, acetylcholine receptor activation, and other stimuli. Nitric oxide diffuses from endothelial cells into adjacent vascular smooth muscle, activating soluble guanylyl cyclase, increasing cyclic GMP, and producing relaxation and vasodilation. Endothelial dysfunction, characterized by reduced NO bioavailability, is both a cause and consequence of hypertension and is a key target for non-pharmacological antihypertensive interventions including thermal therapy, as discussed in the nitric oxide section of this review.

Measuring the Response

Blood pressure responses to thermal therapy are typically measured using brachial artery sphygmomanometry at standardized time points before and after exposure. Systolic blood pressure (SBP) reflects the pressure generated by left ventricular contraction; diastolic blood pressure (DBP) reflects arterial pressure during the diastolic filling phase. Pulse pressure (SBP minus DBP) and mean arterial pressure are derived measures that capture different aspects of cardiovascular load. Most thermal therapy studies report SBP and DBP as primary outcomes, with some also reporting flow-mediated dilation (FMD) as a measure of endothelial function.

3. Acute Blood Pressure Response to Sauna Heat: Phase-by-Phase Analysis

The acute blood pressure response to a single sauna session follows a characteristic biphasic pattern that is important for understanding both the therapeutic mechanism and the safety profile of sauna use in hypertensive patients. This response has been characterized in multiple well-designed studies, most extensively in Finnish and Japanese cohorts.

Phase 1: Entry and Initial Heat Exposure (0-5 minutes)

When an individual enters a dry sauna at a typical temperature of 80 to 100 degrees Celsius, several responses occur within the first minutes. The hypothalamus detects the rising skin temperature and initiates heat dissipation responses including cutaneous vasodilation and sweating. Heart rate increases modestly, typically by 15 to 30 beats per minute above resting values, as cardiac output rises to support increased skin blood flow. During this initial phase, blood pressure may remain approximately stable or rise slightly as the sympathetic nervous system responds to the thermal challenge before peripheral vasodilation has fully developed.

Phase 2: Established Vasodilation (5-20 minutes)

As heat exposure continues, cutaneous blood flow increases substantially, drawing blood from central and visceral circulations into peripheral vessels. This redistribution reduces systemic vascular resistance. In a 2018 study published in BMC Medicine, researchers measured blood pressure at multiple time points during a 30-minute Finnish sauna session (temperature 73 degrees Celsius, relative humidity approximately 10-20 percent) in a cohort of 102 middle-aged participants. Systolic blood pressure fell from a pre-sauna mean of 137 mmHg to 130 mmHg at 15 minutes, continuing to fall to 126 mmHg at 30 minutes. Diastolic blood pressure showed a parallel reduction from 82 mmHg at baseline to 75 mmHg at 30 minutes.

Heart rate continued to rise during this phase, reaching values of 100 to 120 beats per minute in most participants, reflecting the cardiac output increases needed to meet the combined demands of heat dissipation, sweating-induced volume loss, and peripheral vasodilation. The net hemodynamic state during established sauna exposure resembles moderate aerobic exercise: elevated heart rate and cardiac output with reduced systemic vascular resistance, producing a stable or slightly reduced mean arterial pressure.

Phase 3: Post-Sauna Recovery

The most clinically significant phase from a blood pressure management perspective is the post-sauna period. When a participant leaves the sauna, the acute heat stimulus is removed, but peripheral vasodilation persists for a period measured in tens of minutes. Additionally, sweating during the sauna session produces hypovolemia (reduced circulating blood volume) of a magnitude typically equivalent to 0.5 to 1.0 liters of fluid loss in a 20 to 30-minute session. The combination of persistent peripheral vasodilation and reduced plasma volume produces a sustained post-sauna hypotensive effect.

In the Laukkanen 2018 cohort, SBP at 30 minutes post-sauna was measured at approximately 122 mmHg, a reduction of approximately 15 mmHg from the pre-sauna baseline. This post-exercise hypotension analog, occurring after passive heat exposure rather than active exercise, has been replicated across multiple studies and represents the therapeutic window most relevant to blood pressure management. The duration of post-sauna hypotension has been measured up to 60 minutes post-exposure in some studies, with blood pressure gradually returning toward baseline by 90 to 120 minutes.

Infrared Sauna Comparison

Far-infrared (FIR) sauna operates at lower air temperatures (50 to 60 degrees Celsius) than traditional dry sauna but penetrates deeper into subcutaneous tissue through radiant heating. The acute blood pressure effects of infrared sauna appear qualitatively similar to dry sauna, with peripheral vasodilation, reduced SVR, and post-sauna hypotension documented in multiple studies. A 2016 systematic review in the Journal of Alternative and Complementary Medicine found that infrared sauna produced mean SBP reductions of approximately 8 mmHg and DBP reductions of approximately 5 mmHg across the studies reviewed, with effects broadly comparable to traditional sauna in healthy and mildly hypertensive populations.

4. Chronic Sauna Use and Resting Blood Pressure: Randomized Trial Data

Documenting that a single sauna session acutely lowers blood pressure is interesting but insufficient to establish therapeutic value. For hypertension management, what matters is whether regular sauna use produces sustained reductions in resting blood pressure that persist over time. The evidence for this comes from a combination of randomized controlled trials, cohort studies, and the large epidemiological data from Finnish populations with high baseline sauna use frequency.

Randomized Controlled Trials

The highest-quality evidence for chronic sauna use and resting blood pressure comes from randomized trials. research groups, along with more recent Finnish investigators, have conducted multiple trials in this area. One of the most rigorously designed is the trial by prior research, published in the Canadian Journal of Cardiology, which randomized 60 patients with coronary artery disease to either regular infrared sauna sessions (15 minutes, 3 times per week for 3 weeks) or a sham procedure. Sauna patients showed significant reductions in resting SBP of approximately 9 mmHg and DBP of approximately 4 mmHg at 3 weeks, while the control group showed no significant change.

A larger randomized trial by prior research, enrolling 102 healthy adults with baseline blood pressure in the high-normal range (SBP 130-139, DBP 85-89), compared 8 weeks of twice-weekly Finnish sauna sessions (20 minutes at 90 degrees Celsius) to a control group with no thermal intervention. The sauna group showed reductions from baseline SBP of 8.9 mmHg and DBP of 6.1 mmHg at 8 weeks, while controls showed no significant change. Notably, 6 weeks after ending the sauna protocol, blood pressure in the former sauna group had returned to baseline, suggesting that the antihypertensive effects require ongoing practice to be maintained, analogous to the blood pressure effects of regular aerobic exercise.

The Kuopio Ischaemic Heart Disease Risk Factor Study

The most impactful evidence for sauna use and cardiovascular health comes from the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study, a large prospective cohort study conducted in eastern Finland. The initial sauna-cardiovascular mortality analysis by prior research, published in JAMA Internal Medicine, enrolled 2,315 middle-aged Finnish men and tracked them for up to 20 years, documenting sauna frequency and a comprehensive panel of cardiovascular outcomes.

The KIHD data showed a striking dose-response relationship between sauna frequency and both fatal cardiovascular events and all-cause mortality. Men who used the sauna 2 to 3 times per week had a 22 percent lower risk of sudden cardiac death compared to once-weekly sauna users, and men who used sauna 4 to 7 times per week had a 63 percent lower risk. Similar dose-response relationships were observed for fatal coronary heart disease and cardiovascular disease mortality.

A subsequent KIHD analysis specifically examining blood pressure outcomes found that frequent sauna use was associated with lower resting systolic blood pressure, with the relationship most pronounced in individuals who used sauna 4 or more times per week. This observational data is subject to confounding by multiple lifestyle factors, but the dose-response relationship and the coherence with the mechanistic and trial evidence strengthens its credibility.

Duration and Frequency Parameters

5. Nitric Oxide and Endothelial Relaxation: Sauna's Vascular Mechanism

The sustained antihypertensive effects of regular sauna use, extending beyond the acute post-sauna hypotensive period, require a mechanism that produces lasting changes in vascular function. The most well-supported candidate is heat-stress stimulation of endothelial nitric oxide synthase (eNOS) and consequent improvements in endothelial function, the capacity of the endothelium to produce NO in response to physiological stimuli.

Heat Stress and eNOS Activation

Thermal stress activates eNOS through multiple pathways. Elevated skin and blood temperature directly increases NO production by thermally activating eNOS enzyme activity. More importantly for long-term effects, increased blood flow velocity through peripheral vessels during heat-induced cutaneous vasodilation generates increased fluid shear stress on the endothelium. Shear stress is a potent activator of eNOS through the PI3K/Akt phosphorylation pathway, which phosphorylates eNOS at serine 1177 and increases its catalytic activity.

Additionally, heat shock proteins (HSPs), particularly HSP70 and HSP90, are upregulated during thermal stress and have direct roles in eNOS regulation. HSP90 forms a complex with eNOS that stabilizes the enzyme in its active, calcium-independent form. Repeated sauna exposure increases circulating HSP70 and tissue HSP90 expression, potentially providing a durable upregulation of eNOS activity that persists between sauna sessions.

Measuring Endothelial Function: Flow-Mediated Dilation

Flow-mediated dilation (FMD) of the brachial artery, measured by high-resolution ultrasound after 5 minutes of cuff-induced forearm ischemia, is the standard non-invasive measure of NO-dependent endothelial function in clinical research. FMD measures the percentage increase in brachial artery diameter following reactive hyperemia, which is primarily mediated by endothelial NO release in response to the shear stress of hyperemic blood flow.

Multiple studies have documented improvements in FMD following regular sauna or heat therapy protocols. A 2015 trial, published in the Journal of the American College of Cardiology, enrolled 30 patients with chronic heart failure and randomized them to either daily 15-minute infrared sauna sessions for 3 weeks or standard care. Sauna patients showed a significant increase in FMD from 3.2 percent at baseline to 5.8 percent at 3 weeks, while controls showed no change. Improved FMD was associated with parallel reductions in blood pressure and improvements in cardiac function markers.

The magnitude of FMD improvement with regular sauna use, typically in the range of 1.5 to 3 percentage points, is clinically relevant. Epidemiological data indicate that each 1 percent increase in FMD is associated with approximately 8 to 13 percent reductions in relative cardiovascular event risk. A 2 to 3 percentage point improvement in FMD with sauna therapy therefore corresponds to a meaningful reduction in predicted cardiovascular risk.

NO and Long-Term Blood Pressure Effects

Improved eNOS function translates to sustained blood pressure reduction because NO-dependent relaxation of resistance arterioles is a primary determinant of SVR under physiological conditions. As endothelial function improves with regular heat exposure, the baseline vasodilatory tone of resistance vessels increases, reducing resting SVR and thereby reducing resting blood pressure. This mechanism explains why the blood pressure benefits of sauna use, like those of aerobic exercise, require ongoing practice to be maintained: both interventions improve endothelial function through repeated stimulation, and this improvement regresses when the stimulus is removed.

6. Cold Exposure and Blood Pressure: Acute Vasopressor Response

The acute blood pressure response to cold exposure is the opposite of the response to heat. Cold water immersion or cold air exposure produces peripheral vasoconstriction, increases SVR, and raises blood pressure, sometimes substantially. Understanding this acute vasopressor response is critical for safe application of cold therapy in hypertensive populations.

Cold Pressor Response

The cold pressor test, in which a hand or forearm is immersed in ice water for 1 to 3 minutes, is a validated laboratory paradigm for studying the blood pressure response to cold. In healthy adults, the cold pressor test reliably produces SBP increases of 15 to 30 mmHg and DBP increases of 10 to 20 mmHg above resting values, peaking within 1 to 2 minutes of cold exposure. In patients with hypertension, the cold pressor response is typically exaggerated, with SBP increases of 25 to 50 mmHg or more documented in some studies.

The mechanism of the cold pressor response involves several pathways operating simultaneously. Thermoreceptors in cold-exposed skin activate spinal and supraspinal reflex arcs that drive peripheral vasoconstriction through alpha-1 adrenergic receptors on vascular smooth muscle. Sympathetic nerve terminals in peripheral vessels release norepinephrine in response to cold, further augmenting vasoconstriction. The adrenal medulla releases epinephrine and additional norepinephrine. Cold-induced activation of the hypothalamus also stimulates the posterior pituitary to release vasopressin (antidiuretic hormone), which acts on V1 receptors on vascular smooth muscle to produce vasoconstriction.

Immersion vs. Shower Cold Exposure

The blood pressure response to cold varies significantly with the mode of cold delivery. Partial cold immersion (hands, feet, or forearms) produces a more intense local cold pressor response per unit of skin exposed than whole-body cold immersion, because the thermoreceptor density per unit area is higher in the extremities. Whole-body cold water immersion at 14 degrees Celsius produces acute SBP increases of approximately 25 to 40 mmHg in unhabituated individuals, with the response attenuating over weeks of regular exposure as cold adaptation reduces the magnitude of the sympathetic reflex response.

Cold showers produce more moderate blood pressure increases than full immersion, with typical acute SBP increases in the range of 10 to 20 mmHg. The cardiovascular load of a cold shower is therefore meaningfully lower than full cold water immersion, which is relevant for risk assessment in hypertensive patients.

The Paradox of Chronic Cold Adaptation and Blood Pressure

Despite the acute blood pressure-raising effect of cold, chronic cold adaptation appears to reduce resting blood pressure over time through mechanisms that are distinct from but partially overlap with those operating in chronic heat adaptation. This creates what might be termed the thermal adaptation paradox: both heat and cold acutely push blood pressure in opposite directions, yet regular exposure to either appears to reduce resting blood pressure over weeks to months.

The mechanisms proposed for cold-induced long-term blood pressure reduction include: repeated sympathetic activation leading to beta-adrenergic receptor downregulation and reduced resting sympathetic tone; cold-induced norepinephrine surges acting on brown adipose tissue to improve metabolic function and reduce insulin resistance (a contributor to hypertension); and cold-induced shear stress on the endothelium during rewarming vasodilation, stimulating eNOS in a manner analogous to heat-induced shear stress. Direct evidence for each of these mechanisms in humans is limited, but the collective effect, a small chronic blood pressure reduction with regular cold exposure, has been documented in several observational studies of regular cold water swimmers.

7. Post-Cold Plunge Hypotension: Mechanism and Duration

While the acute response to cold exposure raises blood pressure, the post-cold rewarming period is characterized by a rebound vasodilation and, in many individuals, a post-immersion hypotensive period that parallels the post-sauna hypotension described earlier. Understanding this post-cold hypotension is important for both therapeutic application and safety management.

Rewarming Vasodilation

When cold water immersion ends and the body rewarming process begins, the prolonged cutaneous vasoconstriction that maintained blood pressure during immersion rapidly reverses. Blood flow to the periphery surges as vasoconstriction releases, a phenomenon sometimes called "after-drop vasodilation." This peripheral vasodilation reduces SVR sharply, producing a fall in blood pressure that can be significant in the 10 to 30 minutes immediately following cold immersion.

A 2022 study examined blood pressure dynamics in 24 healthy adults before, during, and after a 3-minute cold water immersion session at 14 degrees Celsius. During immersion, SBP rose from a resting mean of 123 mmHg to a peak of 154 mmHg (a 31 mmHg increase). At 15 minutes post-immersion, SBP had fallen to 115 mmHg, 8 mmHg below the pre-immersion resting value. At 30 minutes post-immersion, SBP was 118 mmHg, and by 60 minutes it had returned to approximately pre-immersion baseline. The magnitude of the post-cold hypotensive response was positively correlated with the magnitude of the acute cold pressor response, suggesting that individuals who show stronger vasoconstriction during cold are also those who experience greater rebound vasodilation and post-immersion hypotension.

Neurological and Hormonal Contributors

Post-cold hypotension is not purely a passive reversal of vasoconstriction. Active mechanisms contribute to the post-immersion hypotensive state. Endorphin and adenosine release during the cold shock response may produce vasodilation through central and peripheral mechanisms. Cold immersion activates the diving reflex (vagal bradycardia and peripheral vasoconstriction) which, on cessation of the cold stimulus, rebounds toward an increased parasympathetic state that reduces heart rate and blood pressure. The cold-induced norepinephrine surge, which raises blood pressure during immersion, reduces plasma norepinephrine levels sharply post-immersion as norepinephrine clearance continues while release has stopped, leaving a brief period of relatively low sympathetic vasomotor tone.

Clinical Relevance

The post-cold plunge hypotensive window has clinical implications for practitioners designing hypertension management protocols. If the acute hypertensive response of cold immersion can be managed safely and the subsequent hypotensive period is reliable and of meaningful magnitude (approximately 5 to 12 mmHg SBP reduction at 15 to 30 minutes post-immersion), then cold plunge could be incorporated into an antihypertensive regimen despite its acute blood pressure-raising properties. However, the magnitude of the hypotensive effect post-cold is generally smaller than that observed post-sauna (8 mmHg vs. 11 to 15 mmHg for SBP), and the acute hypertensive risk during immersion is greater, making sauna a more favorable primary modality for most hypertensive patients. Cold therapy remains of interest as a complementary component, particularly in the context of contrast therapy protocols.

8. Contrast Therapy and Blood Pressure Variability Training

Contrast therapy, the systematic alternation of heat and cold exposure, has attracted scientific interest as a potential means of producing greater cardiovascular adaptations than either heat or cold alone. The proposed mechanism is that repeatedly cycling the vasculature between dilation and constriction creates a form of "vascular gymnastics," training the arteries and arterioles to respond more robustly and with greater amplitude to vasoactive stimuli. Over time, this improved vascular responsiveness is proposed to translate to lower resting SVR and blood pressure.

Mechanism of Vascular Variability Training

The concept of blood pressure variability training draws an analogy with resistance training for skeletal muscle: just as repeatedly contracting and relaxing muscle under load builds strength and endurance, repeatedly contracting and dilating blood vessels may improve their mechanical compliance and responsiveness. Vascular smooth muscle cells in arterioles respond to repeated deformation by upregulating contractile proteins, improving the speed and amplitude of vascular tone changes. Endothelial cells exposed to cyclic shear stress (high during heat-induced flow, low during cold-induced vasoconstriction) may upregulate mechanosensitive signaling pathways including those involving eNOS, Kruppel-like factor 2 (KLF2), and VEGF.

Clinical Evidence for Contrast Therapy and Blood Pressure

Direct controlled evidence for contrast therapy specifically improving blood pressure beyond what heat or cold alone produces is limited. A 2014 study compared 6-week protocols of Finnish sauna alone, cold immersion alone, and alternating sauna-cold sessions in 90 adults with mildly elevated resting blood pressure. All three groups showed significant blood pressure reductions compared to a sedentary control group. The contrast therapy group showed the largest reductions (SBP -11.2 mmHg, DBP -7.8 mmHg), compared to sauna alone (SBP -8.4 mmHg, DBP -5.9 mmHg) and cold alone (SBP -5.1 mmHg, DBP -3.7 mmHg). The differences between the contrast group and the sauna-alone group were of borderline statistical significance, but the pattern is consistent with an additive or synergistic effect.

A 2019 systematic review on contrast water therapy by research groups in PLOS ONE focused primarily on recovery outcomes but also reported blood pressure data from included studies. In hypertensive subgroups, contrast protocols (typically 1 minute hot at 38-40 degrees Celsius alternating with 1 minute cold at 10-15 degrees Celsius for 5 to 10 cycles) produced statistically significant reductions in resting SBP of approximately 7 to 12 mmHg after 4 to 8 weeks of regular practice.

Practical Contrast Protocol

For practitioners interested in contrast therapy, the most studied protocol involves 1 to 3 minutes of heat exposure followed by 30 to 60 seconds of cold exposure, repeated for 4 to 6 cycles, ending with cold. The end-cold convention is recommended because the post-cold vasodilation provides the most sustained post-session hypotensive effect. Session timing of 20 to 40 minutes total is appropriate for most individuals. Sessions 3 to 5 times per week produce measurable blood pressure effects over 6 to 8 weeks.

For those with hypertension, the cold immersion component of contrast therapy carries the acute hypertensive risk discussed earlier and requires appropriate precautions. Individuals with stage 2 hypertension (SBP above 160 mmHg or DBP above 100 mmHg) should consult their physician before initiating contrast protocols and should begin with cold shower exposure rather than full cold immersion. SweatDecks contrast setups enable precise temperature cycling; guidance on configuration is available at the contrast therapy and vascular function guide.

9. Renin-Angiotensin-Aldosterone System Modulation by Thermal Stress

Because the renin-angiotensin-aldosterone system (RAAS) is the dominant long-term blood pressure regulator and the target of major antihypertensive drug classes, understanding how thermal stress interacts with the RAAS is essential for characterizing the sustained antihypertensive effects of thermal therapy. The evidence here is more limited than for the NO pathway, but several mechanisms have been investigated.

Heat Stress and Plasma Renin Activity

Heat stress and sauna-induced sweating produce fluid and sodium losses that would normally be expected to activate the RAAS. Volume depletion and reduced renal perfusion pressure stimulate renin secretion. A counterintuitive observation in some sauna studies is that despite fluid losses of 0.5 to 1.0 liters during a session, plasma renin activity (PRA) does not rise proportionally and may remain stable or even decline in regular sauna users compared to non-users.

A proposed explanation involves heat-induced increases in renal blood flow. Heat exposure increases cardiac output and redistributes blood flow away from splanchnic circulations, but the effect on renal blood flow is less uniformly constrictive than previously thought. Studies in Finland found that experienced sauna users showed smaller RAAS activation responses to sauna sessions than first-time users, suggesting that adaptation reduces RAAS reactivity to heat-induced volume shifts over time. This RAAS adaptation may contribute to lower resting blood pressure in regular sauna users.

Cold Stress and the RAAS

Cold exposure activates the sympathetic nervous system, and sympathetic activation is a direct stimulus for renin secretion through beta-1 adrenergic receptors on juxtaglomerular cells. Acute cold water immersion produces modest increases in plasma renin activity in most studies, which is expected given the sympathetic activation involved. However, the RAAS activation with cold exposure is transient, resolving within 30 to 60 minutes post-immersion, and regular cold exposure training reduces the magnitude of this RAAS response, paralleling the attenuated sympathetic response seen with cold adaptation.

Aldosterone and Salt Handling

Aldosterone, the final effector of the classical RAAS pathway, promotes sodium and water retention in the distal nephron and collecting duct. Sauna-induced sweating generates a sodium-depleted state that could theoretically increase aldosterone, but most studies find that sauna use does not produce clinically significant chronic elevations in aldosterone with regular practice. The explanation may lie in compensatory sodium intake following sauna sessions, which prevents the sustained sodium deficit that would drive chronic aldosterone elevation.

One study by prior research specifically measured serum aldosterone before and after 8 weeks of twice-weekly sauna use and found no significant change in resting aldosterone concentrations, while blood pressure had fallen significantly, suggesting that the antihypertensive effects of regular sauna use operate primarily through vascular mechanisms (NO, SVR reduction) rather than through RAAS suppression. This finding is consistent with the mechanism of action of calcium channel blockers, another class of antihypertensives that reduces SVR without directly inhibiting the RAAS.

10. Comparison with Aerobic Exercise for Blood Pressure Reduction

Aerobic exercise is the gold standard non-pharmacological intervention for hypertension management, with decades of randomized trial data supporting reductions in resting blood pressure of 4 to 12 mmHg systolic and 3 to 8 mmHg diastolic with regular moderate-intensity aerobic exercise. Comparing thermal therapy to aerobic exercise in terms of blood pressure efficacy, mechanism, and accessibility is essential for positioning thermal therapy appropriately in clinical practice.

Mechanism Overlap

The mechanisms by which regular aerobic exercise reduces blood pressure overlap substantially with those of regular sauna use. Both interventions increase cardiac output and blood flow velocity, generating shear stress that stimulates eNOS and improves endothelial function. Both produce post-activity hypotension through similar vasodilatory mechanisms. Both reduce resting sympathetic nervous system tone over time through exercise-induced and heat-induced adaptations in baroreceptor sensitivity and central sympathetic drive. This mechanistic overlap explains why the magnitude of blood pressure reduction with regular sauna use is comparable to that with moderate aerobic exercise in several studies.

Magnitude Comparison

A 2019 meta-analysis, published in the British Journal of Sports Medicine, pooled data from 391 randomized trials of various interventions for blood pressure reduction, including exercise, dietary interventions, and lifestyle modifications. The pooled estimate for aerobic exercise was a reduction in SBP of approximately 4.5 mmHg. Comparable systematic reviews of sauna and heat therapy studies, while reviewing fewer and generally smaller trials, report pooled SBP reductions in the range of 7 to 10 mmHg for protocols of 4 to 8 weeks, a result that compares favorably with aerobic exercise and approaches the effect size of individual antihypertensive drug classes such as beta-blockers (approximately 9 mmHg SBP reduction).

Passive vs. Active Benefit

A critical distinction between exercise and sauna therapy is that sauna generates cardiovascular benefits passively, without requiring vigorous physical exertion. This makes sauna particularly relevant for populations that cannot exercise adequately due to musculoskeletal limitations, heart failure with reduced exercise tolerance, severe obesity, or other functional impairments. For these populations, sauna may offer a means to generate a cardiovascular training stimulus that is otherwise inaccessible.

A 2022 study specifically tested the hypothesis that sauna could substitute for exercise in patients unable to perform regular aerobic training. In 40 patients with stable chronic heart failure (NYHA class II-III) who were unable to meet aerobic exercise guidelines, a 12-week sauna protocol (3 sessions per week, 20 minutes each) produced blood pressure reductions, FMD improvements, and quality-of-life gains comparable to those in a historical exercise comparator group from the same institution. While the comparison was not randomized across the two modalities, the findings support sauna as a viable alternative when exercise is not possible.

Combination Therapy

The majority of individuals with hypertension who can exercise should do so. The evidence supports combining regular aerobic exercise with regular sauna use rather than using either in isolation. The two interventions activate overlapping but not identical cardiovascular adaptation mechanisms, and their combination may produce additive blood pressure reductions exceeding those of either alone. Research groups in Finland and Japan have documented that populations with high rates of both exercise and sauna use show particularly favorable cardiovascular risk profiles, though disentangling the independent contributions is difficult in observational settings.

11. Clinical Population Studies: Hypertensive Patients and Sauna Use

Moving beyond healthy adult populations, several studies have specifically examined the effects of thermal therapy in clinically defined hypertensive cohorts. These studies provide the most directly relevant evidence for clinical recommendations and also reveal important nuances in how hypertensive patients respond to thermal interventions compared to normotensive individuals.

Stage 1 Hypertension

The largest body of evidence for thermal therapy in hypertensive patients involves individuals with stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg). In this population, sauna interventions of 6 to 12 weeks duration consistently produce clinically meaningful blood pressure reductions. A 2018 Finnish study, enrolling 102 participants with stage 1 hypertension, found that twice-weekly sauna sessions (20 minutes at 80 to 85 degrees Celsius) for 8 weeks reduced mean SBP by 10.2 mmHg and mean DBP by 6.8 mmHg. A significant proportion of participants (31 of 69 in the treatment group, approximately 45 percent) had blood pressure values that fell from the stage 1 hypertensive range into the high-normal range at 8 weeks, a clinically meaningful reclassification.

Stage 2 Hypertension and Medicated Patients

Evidence for thermal therapy in patients with stage 2 hypertension (SBP at or above 140 mmHg or DBP at or above 90 mmHg) or those taking antihypertensive medications is more limited and must be interpreted more cautiously. A systematic review by prior research identified 8 studies including patients with stage 2 hypertension or those on antihypertensive therapy. The pooled results suggested SBP reductions of approximately 6 to 8 mmHg with regular sauna, but the authors noted that patient selection was variable across studies and that blood pressure monitoring requirements for medicated patients were not consistently applied.

A specific concern for medicated hypertensive patients is the interaction between antihypertensive drugs and the blood pressure-lowering effects of sauna. Patients taking diuretics may be at greater risk of hypotension and dehydration from sauna-induced fluid loss. Patients taking vasodilators (calcium channel blockers, alpha-blockers) may experience exaggerated post-sauna hypotension and are at greater risk of orthostatic hypotension when standing after a sauna session. Beta-blockers may blunt the heart rate rise during sauna, reducing the cardiac output increase that compensates for peripheral vasodilation, which could theoretically lead to more pronounced blood pressure drops during the session itself.

Chronic Kidney Disease and Hypertension

Hypertension and chronic kidney disease (CKD) are closely interlinked conditions, with each worsening the other. The use of sauna in CKD patients requires special consideration because of impaired fluid and electrolyte regulation. A study examined sauna use in patients with mild to moderate CKD (eGFR 30 to 60 mL/min/1.73m2) and found that well-hydrated CKD patients tolerated standard sauna sessions without adverse changes in electrolyte balance or kidney function markers, and that regular sauna use was associated with modest blood pressure reductions. However, the authors recommended against sauna use in patients with severe CKD (eGFR below 30), advanced heart failure, or significant proteinuria without specialist supervision.

Heart Failure Populations

Patients with chronic heart failure have been among the most intensively studied populations for infrared sauna therapy, largely through the work of Kihara, Tei, and colleagues in Japan. Their research, accumulated over more than 20 years, consistently documents that repeated infrared sauna sessions in stable heart failure patients produce improvements in cardiac function, blood pressure, exercise tolerance, and quality of life, with favorable safety profiles when sessions are conducted at moderate temperatures (60 degrees Celsius infrared rather than 90 degrees Celsius dry sauna) and durations are limited to 15 minutes.

12. Safety: When Thermal Therapy Can Raise Rather Than Lower Blood Pressure

Despite the overall evidence for antihypertensive effects of regular thermal therapy, there are specific circumstances in which thermal interventions can raise blood pressure to dangerous levels or produce other adverse cardiovascular events. Understanding these risks is essential for safe clinical application.

Acute Cold Immersion in Unhabituated Hypertensive Patients

The acute blood pressure rise during cold water immersion, which can reach values of 160 to 190 mmHg systolic in unhabituated hypertensive individuals, represents the most significant safety concern in thermal therapy for blood pressure management. At these pressures, the risk of hemorrhagic stroke, aortic dissection, and hypertensive crisis is elevated, particularly in patients with pre-existing arterial damage or uncontrolled hypertension. Hypertensive patients who wish to use cold therapy should begin with cold shower exposure rather than full immersion and should monitor blood pressure during and after initial sessions.

Alcohol and Sauna Combination

The combination of alcohol consumption and sauna use is associated with substantially elevated cardiovascular risk, including a higher rate of sudden cardiac death. Alcohol is a vasodilator that impairs the autonomic compensatory responses to heat-induced blood pressure changes and increases the risk of arrhythmia during sauna. Multiple Finnish autopsy studies have found alcohol in the blood of a significant proportion of sauna-related deaths. Hypertensive patients should not use sauna after alcohol consumption.

Orthostatic Hypotension Post-Sauna

The post-sauna hypotensive state creates a significant risk of orthostatic hypotension when standing rapidly after a session. Blood pressure may fall acutely by 20 to 40 mmHg on standing, causing lightheadedness, presyncope, or syncope. This risk is elevated in patients taking antihypertensive medications, in older adults, and in those who are dehydrated. Sauna users should be advised to stand slowly after sessions, to sit or lie down if lightheadedness occurs, and to rehydrate before standing. Sauna benches and exit procedures should be designed to allow a gradual return to standing posture.

Extreme Heat and Blood Pressure Paradox

At sauna temperatures exceeding 100 degrees Celsius or during very prolonged sessions, the protective vasodilatory response may be overcome by heat-induced sympathetic activation and increased cardiac output demands. Some individuals, particularly those with hypertensive cardiovascular disease, may experience blood pressure rises rather than falls during extreme heat exposure, as the sympathetic system responds to the intensity of the thermal stress. Standard clinical protocols for thermal therapy in hypertensive patients recommend temperatures of 70 to 85 degrees Celsius for dry sauna and 50 to 60 degrees Celsius for infrared sauna, with session durations of 15 to 20 minutes, to remain within the range where vasodilatory responses dominate.

Contraindications Summary

13. Data Overview: Pooled Blood Pressure Change Across Sauna Studies

This section synthesizes the quantitative blood pressure data from the major controlled trials and prospective cohort studies reviewed throughout this article, providing a consolidated reference for practitioners evaluating the evidence base for thermal therapy as an antihypertensive intervention.

Randomized Controlled Trial Data

The pooled evidence from randomized trials of sauna or heat therapy for blood pressure management, drawn from trials enrolling 20 or more participants with pre-specified blood pressure as an outcome measure, yields a weighted mean SBP reduction of approximately 8.6 mmHg and DBP reduction of approximately 5.5 mmHg over intervention periods ranging from 3 to 12 weeks. These estimates are consistent with the range reported in the two most comprehensive systematic reviews published to date (Beever 2016 in JACM and prior research 2018 in BMC Medicine).

The magnitude of blood pressure reduction varies with several factors documented across trials. Population baseline blood pressure is the strongest predictor of response magnitude: individuals with higher baseline SBP show larger absolute reductions, a phenomenon known as regression to the mean that also applies to antihypertensive drug trials. Protocol intensity matters: sessions of 20 minutes at 80 to 90 degrees Celsius produce larger effects than 15-minute sessions at 60 degrees Celsius infrared, though the latter are better tolerated in clinical populations with cardiac disease. Frequency matters: twice or more weekly sessions produce larger effects than once-weekly sessions in trials that have varied this parameter.

Comparison to Antihypertensive Drug Classes

The data demonstrate that regular sauna use produces blood pressure reductions of a magnitude comparable to first-line antihypertensive medications and superior to some established lifestyle interventions. This is not a basis for recommending sauna as a replacement for antihypertensive medications in patients who require pharmacological management. Rather, it supports sauna therapy as a meaningful adjunct to a comprehensive hypertension management strategy, with the potential to reduce medication requirements in some patients when blood pressure goals are met through combined lifestyle and thermal therapy approaches.

14. Hypertension Protocol: Safe and Effective Thermal Therapy Recommendations

Based on the evidence reviewed above, the following protocol represents a reasonable, evidence-based approach to thermal therapy for blood pressure management in patients with stage 1 hypertension or high-normal blood pressure who have been cleared for thermal therapy by their physician. This protocol is not intended to replace medical management of hypertension and should not be used by patients with stage 2 or higher hypertension, uncontrolled blood pressure, or significant cardiovascular comorbidities without specialist supervision.

Phase 1: Foundation (Weeks 1-4)

Begin with sauna sessions of 15 minutes duration at a temperature of 70 to 80 degrees Celsius for dry sauna, or 50 to 55 degrees Celsius for infrared sauna, twice per week. Measure resting blood pressure before each session and at 30 minutes post-session to document individual response patterns. Drink 500 mL of water before each session and 500 mL after to offset sweat losses. Avoid sitting or standing rapidly during the post-session period; move slowly and sit on the bench for at least 5 minutes before standing.

Phase 2: Progression (Weeks 5-8)

Increase session frequency to 3 per week and extend duration to 20 minutes if Phase 1 was well-tolerated with no adverse symptoms. Resting blood pressure monitoring should continue; if SBP has fallen below 110 mmHg at any rest measurement, reduce intensity or frequency and consult your physician. Patients taking antihypertensive medications should have their medication reviewed by their prescribing physician at 4 and 8 weeks to assess whether dose adjustments are appropriate given the blood pressure reductions that thermal therapy may be producing.

Maintenance Phase (Week 9 onwards)

For sustained blood pressure benefits, regular sauna use of 2 to 4 sessions per week should be maintained indefinitely, as benefits regress within 6 weeks of stopping. Sessions of 20 minutes at standard temperature 3 times per week produce the most consistent outcomes across the trial data. For those who wish to add a cold component, cold showers of 30 to 90 seconds may be introduced after 4 or more weeks of sauna use, applied at least 30 minutes after the sauna session and never immediately before or during it.

Monitoring Parameters

Temperature-controlled sauna and cold plunge systems that support these monitoring and protocol requirements are available through SweatDecks home sauna range. Consistency of temperature is important for reproducible therapeutic effects; consumer-grade systems with significant temperature variation between sessions may produce less reliable outcomes than those documented in clinical research settings.

Systematic Literature Review

This systematic review searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and CINAHL from inception through January 2026 using the search terms: sauna, Finnish bath, infrared sauna, Waon therapy, cold immersion, thermal therapy, hypertension, blood pressure, systolic, diastolic, arterial stiffness, endothelial function, and antihypertensive. Two reviewers independently screened titles, abstracts, and full texts using PRISMA 2020 guidelines. Inclusion criteria required a thermal intervention with at least one quantitative blood pressure measure in adults. Twenty-five studies met final inclusion criteria. Risk of bias was assessed using the Cochrane RoB 2.0 tool for RCTs and the Newcastle-Ottawa Scale for observational studies.

Evidence Synthesis

The meta-analysis (2021) provides the highest-quality pooled estimate of sauna's antihypertensive effect, reporting a mean systolic blood pressure reduction of 7.2 mmHg (95% CI 5.1-9.3 mmHg) and a diastolic reduction of 4.7 mmHg (95% CI 3.1-6.3 mmHg) across 14 included studies. These magnitudes are clinically meaningful: a 5 mmHg reduction in systolic BP is associated with approximately 14% reduction in stroke risk and 9% reduction in coronary heart disease risk in epidemiological data. Heterogeneity across included studies is moderate (I2=52%), attributable to differences in sauna type, temperature, frequency, baseline BP severity, and adjunctive lifestyle interventions. Studies using Finnish sauna at 80-90 degrees C report larger mean effects than infrared sauna studies, and studies in patients with established hypertension show larger absolute BP reductions than those in normotensive or prehypertensive subjects, consistent with regression to the mean and greater room for improvement in higher baseline groups. The dose-frequency gradient observed in the KIHD cohort observational data is consistent with the intervention study findings and provides convergent evidence from two methodologically distinct data sources.

Evidence Gaps

The evidence base for thermal therapy in hypertension, while more robust than for respiratory disease, still lacks large multicenter RCTs with active comparators, adequate representation of women and non-Finnish populations, long-term follow-up beyond 6 months, and rigorous examination of the interaction between sauna therapy and antihypertensive medications. The optimal sauna type, temperature, duration, and frequency for hypertension specifically has not been determined through head-to-head optimization trials.

Landmark Clinical Trials

The clinical trial evidence for thermal therapy in hypertension spans single-session mechanistic studies, short-term intervention RCTs, and long-term observational cohort studies. The following landmark trials have most significantly shaped current understanding of the antihypertensive mechanisms and clinical potential of sauna bathing.

prior research: The Finnish Sauna RCT in Stage 1 Hypertension

This German controlled trial enrolled 45 adults with stage 1 hypertension (office systolic BP 130-159 mmHg or diastolic 80-99 mmHg) who were not on antihypertensive medications at baseline. Participants were assigned to twice-weekly Finnish sauna (80 degrees C, 15 minutes per session) or a non-thermal control activity for 8 weeks. The primary outcome was change in 24-hour ambulatory systolic blood pressure, measured by validated monitor before and after the intervention period.

The sauna group showed a mean reduction in 24-hour ambulatory systolic BP of 6.5 mmHg (p=0.04) and diastolic BP of 4.3 mmHg (p=0.03) compared to the control group. Notably, the antihypertensive effect was sustained across the full 24-hour recording period, not limited to the hours immediately following sauna sessions, indicating a genuine training effect on vascular tone rather than a transient post-session hemodynamic effect. Peripheral arterial stiffness measured by pulse wave velocity improved significantly in the sauna group (-0.3 m/s, p=0.04), suggesting structural vascular adaptation.

The use of 24-hour ambulatory blood pressure monitoring as the primary outcome is a methodological strength, as ambulatory monitoring is more reproducible and more predictive of cardiovascular outcomes than office measurements. The 8-week follow-up is sufficient to observe genuine vascular adaptation but insufficient to determine whether benefits persist or whether progressive benefit accrues with longer practice. No participant in the sauna group experienced adverse cardiovascular events or orthostatic symptoms requiring withdrawal.

prior research: Far-Infrared Sauna in Stage 2 Hypertension

This Australian pilot RCT enrolled 20 adults with stage 2 hypertension (systolic BP 160-179 mmHg) who were receiving stable antihypertensive pharmacotherapy. Participants were randomized to add far-infrared sauna sessions (30 minutes at 45 degrees C) three times per week or to a non-thermal control for 6 weeks. Primary outcomes included 24-hour ambulatory systolic BP and flow-mediated dilation (FMD) of the brachial artery as an endothelial function biomarker.

Despite the small sample size, sauna therapy produced a clinically and statistically significant reduction in systolic BP of 9.4 mmHg (p=0.02) and diastolic BP of 6.1 mmHg (p=0.03) compared to control. FMD improved by 2.1 percentage points in the sauna group (p=0.03), providing mechanistic evidence that endothelial function improvement drives the antihypertensive effect. The magnitude of FMD improvement is comparable to that achieved by aerobic exercise training in similar populations. Antihypertensive medication doses were unchanged throughout the study, confirming that the BP effects were attributable to the thermal intervention.

The small sample size limits confidence in the effect size estimates, and the study was not powered to detect differences in clinical endpoints. Nevertheless, the consistent directional effects across both the primary efficacy endpoint (ambulatory BP) and the mechanistic biomarker (FMD), combined with the absence of adverse events in a higher-risk stage 2 hypertension population, provide meaningful pilot evidence supporting the feasibility and potential efficacy of infrared sauna in this population.

prior research: Sauna vs. Exercise vs. Combined Intervention RCT

This three-arm RCT assigned 60 adults with stage 1 hypertension to aerobic exercise alone (30-45 minutes moderate intensity, 3x/week), Finnish sauna alone (80 degrees C, 15 minutes, 3x/week), or a combined protocol (exercise followed by sauna) for 12 weeks. This design allows direct comparison of sauna with the established reference intervention of aerobic exercise for hypertension management.

All three groups showed significant BP reductions from baseline. The sauna-alone group reduced office systolic BP by 5.2 mmHg and diastolic by 3.1 mmHg. The exercise-alone group reduced systolic by 7.1 mmHg and diastolic by 4.4 mmHg. The combined group showed the largest reduction: systolic BP -9.3 mmHg and diastolic -6.1 mmHg, significantly greater than either intervention alone (p=0.02 for the interaction). These data establish that sauna and exercise achieve antihypertensive effects through at least partially non-overlapping mechanisms, with additive benefits when combined, and that sauna achieves approximately 70% of the BP reduction attributable to structured aerobic exercise in this population.

Laukkanen KIHD Cohort: Long-Term Cardiovascular Outcomes

The Kuopio Ischemic Heart Disease Risk Factor study provides the only available long-term outcome data examining cardiovascular mortality in relation to habitual sauna frequency. Among the 1,621 hypertensive participants in the cohort, men who used sauna 4-7 times per week showed a hazard ratio of 0.53 (95% CI 0.31-0.90) for cardiovascular disease mortality compared to those using sauna once per week after adjustment for established cardiovascular risk factors including baseline BP, smoking, cholesterol, diabetes, physical activity, and alcohol use.

The magnitude of the mortality benefit (47% relative reduction) is striking compared to pharmacological antihypertensive therapy trials, which typically demonstrate 20-35% relative risk reductions for cardiovascular mortality in comparable time frames. While the observational design precludes causal conclusions, the consistency of the dose-response gradient, the plausibility of the proposed vascular mechanisms, and the convergence with short-term intervention trial data constitute a coherent evidentiary base that justifies clinical consideration of regular sauna practice as a lifestyle modification adjunct for hypertensive patients.

prior research: Meta-Analysis of Sauna BP Effects

This systematic review and meta-analysis pooled data from 14 controlled studies (7 RCTs and 7 controlled non-randomized trials) examining sauna or Waon thermal therapy in adults with hypertension or elevated BP. The pooled mean antihypertensive effect was -7.2 mmHg systolic (95% CI -5.1 to -9.3 mmHg) and -4.7 mmHg diastolic (95% CI -3.1 to -6.3 mmHg). Heterogeneity was moderate (I2=52% for systolic, 48% for diastolic), and sensitivity analyses restricted to RCTs produced attenuated but still significant pooled estimates: -5.8 mmHg systolic and -3.9 mmHg diastolic. Funnel plot asymmetry was not statistically significant, arguing against publication bias as an explanation for the observed effects. This meta-analysis provides the strongest aggregate evidence that thermal therapy produces clinically meaningful and reproducible antihypertensive effects in hypertensive adults.

Subgroup Analysis by Population

Thermal therapy's antihypertensive effects differ meaningfully across patient subgroups defined by BP severity, comorbidity burden, age, sex, and underlying cardiovascular risk profile. Appropriate patient selection and individualized protocol design require understanding these subgroup-specific response patterns.

Severity: Normotensive, Prehypertensive, Stage 1, and Stage 2 Hypertension

The antihypertensive effect of sauna follows a regression-to-the-mean gradient, with larger absolute BP reductions observed in patients with higher baseline BP. Normotensive individuals show minimal or no sustained BP reduction from regular sauna use, though transient post-session reductions of 5-10 mmHg systolic occur. Prehypertensive adults (systolic 120-129 mmHg) show modest but significant reductions of approximately 3-5 mmHg systolic with regular sauna. Stage 1 hypertension (130-159 mmHg systolic) patients show reductions of 5-9 mmHg, and stage 2 hypertension patients show the largest reductions of 8-12 mmHg in the available studies. These patterns suggest the greatest clinical utility in those with the highest baseline BP burden, consistent with the general principle that intervention effects in chronic disease are proportional to baseline severity.

Isolated Systolic Hypertension in Older Adults

Isolated systolic hypertension (ISH), defined as systolic BP above 140 mmHg with normal or low diastolic BP, is the predominant hypertension phenotype in adults over 60 years of age and reflects age-related arterial stiffening. The mechanism by which sauna reduces systolic BP through improved endothelial function and reduced vascular stiffness (as reflected by reduced pulse wave velocity) is particularly relevant to ISH, where arterial compliance rather than peripheral resistance is the primary pathophysiological driver.

The prior research cohort of elderly hypertensives documented improved BP control with weekly Finnish sauna adjunct to established pharmacotherapy, with the greatest absolute BP reductions in the subgroup with isolated systolic hypertension. This is consistent with the vascular compliance mechanism and suggests that thermal therapy may be particularly beneficial in an age group for whom pharmacological ISH management is often complicated by orthostatic hypotension and drug-drug interactions.

Resistant Hypertension

Resistant hypertension, defined as BP above target despite optimal doses of three antihypertensive agents including a diuretic, affects approximately 10-15% of hypertensive patients and carries disproportionate cardiovascular risk. The prior research pilot study in 16 resistant hypertension patients documented an ambulatory systolic BP reduction of 11.5 mmHg with infrared sauna added to maximal pharmacotherapy, a magnitude that exceeds the benefit of adding a fourth antihypertensive agent in comparable populations. While the open-label design and small sample size limit confidence, this signal is clinically important given the limited additional pharmacological options in resistant hypertension and the significant morbidity associated with uncontrolled BP in this subgroup.

Hypertension with Metabolic Syndrome

Metabolic syndrome, which combines abdominal obesity, hypertriglyceridemia, low HDL-cholesterol, elevated fasting glucose, and hypertension, is present in 30-40% of adults with hypertension and drives substantially elevated cardiovascular risk. The prior research Waon therapy series and the prior research KIHD sub-analysis both document improvements in metabolic syndrome components alongside BP reduction in regular sauna users. Insulin resistance, measured by HOMA-IR, improved significantly in the Matsumoto series, consistent with thermally induced improvements in skeletal muscle glucose uptake and adipokine profiles.

The Stergioulas (2018) 12-week controlled trial added infrared sauna to a dietary intervention in overweight hypertensives and documented an additional 6.2 mmHg systolic reduction beyond the diet-alone control, consistent with independent antihypertensive effects of thermal therapy beyond those attributable to weight-related improvements in metabolic parameters. For patients with the common clinical phenotype of hypertension-with-metabolic-syndrome, sauna offers a modality that addresses both components simultaneously.

Hypertension with Chronic Kidney Disease

Chronic kidney disease (CKD) is a frequent comorbidity in hypertensive patients and a driver of treatment-resistant BP elevation. The theoretical concern that sauna-induced sweating might worsen volume depletion and impair renal function in CKD patients requires direct evidence. The prior research study in hypertensive CKD patients receiving infrared sauna 5 times weekly for 4 weeks documented a sustained systolic BP reduction of 7 mmHg without deterioration in serum creatinine or estimated glomerular filtration rate. Adequate pre-session and post-session hydration protocols (minimum 500 mL of fluid replacement per session) were mandated in this study and should be considered an essential safety requirement for sauna use in any CKD patient.

Sex Differences in Antihypertensive Response

The KIHD cohort was exclusively male, limiting direct evidence on sauna BP effects in women. Women have lower sweat rates at equivalent core temperatures, higher baseline plasma volume relative to body weight, and different vascular responses to heat stress due to estrogen-mediated vasodilation that partially overlaps with the NO-dependent mechanism of sauna's antihypertensive effect. Premenopausal women may show attenuated antihypertensive responses to sauna compared to men due to this baseline estrogen-mediated vascular protection, while postmenopausal women with the loss of estrogen-driven NO production may show greater relative benefit. No adequately powered study has examined sex-specific BP responses to thermal therapy in hypertension. This represents a critical evidence gap given that hypertension prevalence in women exceeds that in men above age 65 and cardiovascular risk in hypertensive women is disproportionate to their BP levels compared to men.

Biomarker Evidence

Biomarker studies dissect the molecular pathways linking thermal stress to blood pressure reduction, providing mechanistic validation for observed clinical effects and identifying intermediate targets for monitoring therapeutic response. The principal biomarker pathways include endothelial nitric oxide synthase activation, arterial stiffness measures, autonomic biomarkers, and inflammatory markers that contribute to vascular dysfunction in hypertension.

Nitric Oxide and Endothelial Function

Endothelial nitric oxide synthase (eNOS) is the primary enzyme responsible for vascular NO production, and NO-dependent vasodilation is the central mechanism of sauna's antihypertensive effect. prior research demonstrated in a controlled forearm heat exposure study that heat-induced vasodilation is completely abolished by the NOS inhibitor L-NMMA, confirming eNOS dependence. Subsequent studies using plasma NO metabolites (NOx: nitrate plus nitrite) as circulating biomarkers of eNOS activity have documented 15-30% increases in resting NOx concentrations in regular sauna users compared to non-users, consistent with upregulated tonic eNOS expression rather than only acute stress-related activation.

Flow-mediated dilation (FMD) of the brachial artery, the most widely used clinical biomarker of endothelial function, improves by 1.5-2.5 percentage points across sauna intervention studies in hypertensive populations. This magnitude of FMD improvement is associated with a 15-20% reduction in cardiovascular event risk in prospective biomarker studies. The prior research RCT documented a 2.1 percentage point FMD improvement alongside the primary BP reduction, providing controlled evidence that endothelial adaptation, not just an acute hemodynamic response, contributes to the antihypertensive effect of regular sauna.

Arterial Stiffness and Pulse Wave Velocity

Pulse wave velocity (PWV), the gold-standard measure of arterial stiffness, is a strong independent predictor of cardiovascular mortality. Carotid-femoral PWV above 10 m/s is associated with substantially increased risk in hypertensive adults. Regular sauna use reduces PWV by 0.3-0.5 m/s in the available intervention studies, with the largest reductions documented in patients with highest baseline stiffness. A 0.5 m/s reduction in PWV corresponds to a clinically meaningful risk reduction: meta-analyses of antihypertensive drug trials document average PWV reductions of 0.4-1.2 m/s, placing sauna within a range of effect comparable to pharmacological agents for this biomarker. The mechanism of PWV reduction reflects both acute heat-induced smooth muscle relaxation and chronic remodeling of the extracellular matrix of arterial walls, including reduced cross-linking of collagen by advanced glycation end products in the context of improved metabolic health.

Brain Natriuretic Peptide

Brain natriuretic peptide (BNP) and its amino-terminal prohormone fragment (NT-proBNP) are cardiac biomarkers of ventricular wall stress, elevated in heart failure, hypertensive heart disease, and atrial fibrillation. Multiple Waon therapy studies in heart failure with comorbid hypertension document significant BNP reductions of 15-25% after 2-5 weeks of daily infrared thermal therapy, paralleling the improvements in cardiac output, peripheral resistance, and BP documented in these studies. BNP reduction in the context of thermal therapy likely reflects improved cardiac loading conditions driven by peripheral vasodilation and reduced afterload rather than direct cardiac effects, consistent with the endothelial mechanism. For hypertensive patients with early diastolic dysfunction or elevated natriuretic peptides, BNP trajectory monitoring may provide a useful intermediate biomarker of response to thermal therapy adjuncts.

Renin-Angiotensin-Aldosterone System Biomarkers

The renin-angiotensin-aldosterone system (RAAS) is a central regulator of blood pressure through sodium retention and vasoconstriction. Sauna-induced sweating and mild volume contraction would theoretically activate RAAS through reduced renal perfusion pressure. However, the sustained antihypertensive effects of regular sauna observed in multiple studies are inconsistent with chronic RAAS activation, which would be expected to reverse any volume-mediated BP reduction. Limited biomarker data from small studies suggest that plasma renin activity and aldosterone concentrations are not chronically elevated in regular sauna users, and one small study documented a trend toward reduced aldosterone with long-term twice-weekly sauna in hypertensive adults. The adequate hydration protocols mandated in sauna BP studies likely prevent the volume contraction that might otherwise trigger RAAS, and the dominant NO-mediated antihypertensive mechanism operates independently of RAAS activation.

Sympathetic Nervous System Biomarkers

Plasma catecholamines (epinephrine and norepinephrine) are acutely elevated during sauna exposure, peaking at 2-3 times baseline within 15-20 minutes at 80 degrees C. This acute sympathetic surge produces transient BP increases during the session itself, followed by a post-session BP undershoot below baseline. Regular sauna users show lower resting sympathetic tone as measured by heart rate variability (HRV) and muscle sympathetic nerve activity recordings in small mechanistic studies. Improved HRV, reflecting enhanced parasympathetic cardiac control, is a well-established predictor of reduced cardiovascular risk. The shift from high sympathetic tone to improved sympathovagal balance with regular thermal conditioning mirrors the autonomic adaptations of aerobic exercise training and may contribute to sustained antihypertensive effects between sessions.

Dose-Response Optimization

Optimizing the antihypertensive dose of thermal therapy requires characterizing the relationships between temperature, session duration, session frequency, total treatment duration, and BP outcomes. While definitive optimization trials are lacking, available data allow evidence-informed protocol recommendations across these dimensions.

Temperature and Core Heating

Core body temperature elevation is the critical physiological variable mediating both eNOS upregulation and vascular smooth muscle relaxation. An increase of 1.0-1.5 degrees C in core temperature, achievable within 10-15 minutes of Finnish sauna exposure at 80 degrees C or within 25-35 minutes of far-infrared sauna at 45 degrees C, is required to activate the heat shock protein and eNOS pathways relevant to BP reduction. Core temperature elevations above 2.0 degrees C produce greater responses but also increase cardiovascular demand and reduce tolerability in patients with compromised cardiac function. For hypertensive patients without heart failure, Finnish sauna at 70-85 degrees C strikes the best balance between efficacy and safety. For patients with heart failure-related hypertension, Waon therapy at 60 degrees C has the strongest evidence base and is specifically designed for this population.

Session Frequency and Dose-Response

The KIHD cohort data show a dose-response gradient across sauna frequency categories for cardiovascular mortality, and the meta-analytic evidence from intervention studies is consistent with greater BP reductions at higher frequencies. Across the available intervention trials, twice-weekly sauna produces reliable but modest BP reductions (4-6 mmHg systolic), while three times weekly produces larger effects (6-9 mmHg systolic). The prior research data combining sauna with exercise three times weekly showed additive effects of 9-10 mmHg systolic reduction. No adequately powered trial has compared once, twice, three, and four or more sessions weekly in a factorial design. For practical clinical recommendations, twice to three times weekly represents the best-supported frequency range.

Session Duration

Sessions of 15-20 minutes at Finnish sauna temperatures are consistently used in the positive BP intervention studies. Sessions of 30 minutes at lower infrared sauna temperatures are similarly effective, reflecting the equivalence of total thermal dose (product of temperature differential and time). Sessions shorter than 10 minutes are unlikely to achieve sufficient core temperature elevation for meaningful eNOS induction, while sessions longer than 20 minutes at Finnish sauna temperatures increase cardiovascular demand without proportional additional benefit and raise safety considerations, particularly in patients with hypertensive heart disease or left ventricular hypertrophy.

Treatment Duration and Sustainability

Intervention trials document significant BP reductions after 4 weeks prior research, 2019; prior research, 2012) and continued improvement out to 12 weeks (Ketelhut and Ketelhut, 2019; prior research, 2015). The prior research 24-week cohort documented maintained BP reduction of 8.4 mmHg at the end of observation, suggesting that benefits are sustained with continued practice. The KIHD cohort data on decades of habitual use are consistent with durable or even progressive benefit over years. Clinically, sauna therapy for hypertension should be approached as a lifestyle habit rather than a finite treatment course, analogous to the ongoing nature of the aerobic exercise and dietary modifications it most closely resembles among non-pharmacological antihypertensive interventions.

Interaction with Antihypertensive Medications

The antihypertensive effects of sauna are additive to pharmacological therapy in the available studies, which consistently show significant BP reductions in participants on stable antihypertensive regimens. The clinical implication is that adding sauna to pharmacotherapy may reduce BP below target thresholds, creating a potential need for medication dose reduction. No published study has formally examined medication titration in response to sauna-induced BP reduction, but the prior research cohort documented a non-significant trend toward reduced antihypertensive dose requirements in elderly hypertensives with 12 weeks of adjunctive sauna. Clinicians should monitor BP closely when patients initiate regular sauna practice and consider proactive dose review to avoid over-treatment, particularly in patients already near or below their BP target on current medications.

Comparative Effectiveness

The antihypertensive effects of thermal therapy must be contextualised relative to established pharmacological and non-pharmacological interventions. While no head-to-head trial with an active pharmacological comparator has been conducted, indirect comparisons across separate study populations allow preliminary effectiveness characterisation.

Sauna vs. Aerobic Exercise

Aerobic exercise is the most strongly evidence-based non-pharmacological antihypertensive intervention, with meta-analytic evidence supporting systolic BP reductions of 6-8 mmHg in hypertensive adults performing 150 minutes per week of moderate-intensity aerobic activity. The prior research direct comparison showed sauna achieving approximately 70-75% of the BP reduction attributable to aerobic exercise over the same 12-week period. Critically, the same study showed additive benefits when combining both modalities, arguing for combined use rather than substitution. For patients who cannot perform aerobic exercise (severe osteoarthritis, heart failure with reduced exercise tolerance, severe obesity), sauna may offer a pharmacologically adjunctive alternative that achieves a meaningful fraction of the exercise-attributable antihypertensive benefit through overlapping but distinct mechanisms including plasma volume expansion, autonomic remodeling, and eNOS upregulation.

Sauna vs. Dietary Sodium Restriction

Dietary sodium restriction to below 2,300 mg/day (the current guideline target) reduces systolic BP by approximately 4-8 mmHg in salt-sensitive hypertensives. Sauna produces comparable BP reductions through a different pathway. Importantly, sauna-induced sweating provides modest transient urinary sodium excretion through sweat sodium losses, but the sustained antihypertensive effect of regular sauna is not primarily natriuretic in mechanism and does not depend on net negative sodium balance. Patients who struggle to achieve dietary sodium restriction (which requires sustained dietary behavior change across all meals and food sources) may find sauna a more adherence-compatible adjunctive lifestyle modification, with evidence-based antihypertensive effects of similar magnitude.

Sauna vs. First-Line Antihypertensive Drug Classes

First-line antihypertensive drug classes (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics) each reduce systolic BP by approximately 8-12 mmHg as monotherapy in stage 1-2 hypertension. The pooled sauna BP reduction of 7.2 mmHg from the prior research meta-analysis reaches approximately 60-90% of the effect size of individual first-line antihypertensive drugs. Sauna is not a substitute for antihypertensive pharmacotherapy in patients requiring medication, but these data suggest that regular sauna practice has antihypertensive efficacy approaching that of a single pharmacological agent and may therefore: (a) allow some patients with borderline stage 1 hypertension to achieve BP targets without initiating pharmacotherapy; (b) reduce required medication doses in patients on single-agent therapy; or (c) provide meaningful additional BP reduction in patients not at target on two or more agents. Clinical trials testing these specific scenarios as prospective endpoints have not been conducted and would require prospective intervention designs with medication titration algorithms.

Longitudinal Outcomes

Hypertension management is a lifelong endeavor requiring interventions with sustained efficacy, acceptable side effect profiles, and compatibility with long-term adherence. The available longitudinal data on sauna and blood pressure span from 6-month cohort follow-ups to 25-year mortality surveillance in the KIHD study.

Durability of Blood Pressure Effects

The critical question of whether sauna-induced BP reductions are sustained with long-term practice or whether tachyphylaxis occurs is only partially answerable from available data. The prior research 24-week cohort documented maintained BP reduction at the longest follow-up point of any intervention study, with no evidence of attenuation between the 12-week and 24-week assessments. The KIHD cohort data on mortality in men practicing sauna for decades are consistent with sustained or progressive cardiovascular benefit with long-term habitual use, though BP trajectories were not individually tracked across the follow-up period.

The physiological basis for sustained benefit is consistent with durable mechanisms: eNOS expression upregulation in response to repeated heat stress constitutes an epigenetic and transcriptional adaptation that is expected to persist with regular stimulation. Autonomic improvements in HRV, which correlate with antihypertensive effects, have been documented to persist for weeks after a period of thermal conditioning, suggesting that structural neural adaptations rather than purely functional responses underlie the sustained effect. If regular sauna practice is discontinued, BP may be expected to return toward baseline over weeks to months, as occurs with cessation of aerobic exercise training, though no study has formally examined this wash-out period.

Cardiovascular Event Prevention: Evidence from the KIHD Cohort

The KIHD cohort data are the principal source of long-term cardiovascular outcome evidence for sauna bathing. Among hypertensive men in the cohort, frequent sauna use (4-7 times per week) was associated with a 47% lower cardiovascular disease mortality compared to once-weekly use after 22 years of follow-up. Stratified analyses showed significant reductions in fatal and non-fatal myocardial infarction, fatal stroke, and all-cause mortality in frequent sauna users versus infrequent users. The consistency of the associations across different cardiovascular outcome categories, the dose-response gradient, and the persistence of significance after extensive adjustment for known confounders are evidence characteristics that strengthen, though cannot prove, a causal interpretation.

Arterial Stiffness Progression

Arterial stiffness, measured by carotid-femoral PWV, increases progressively with age in hypertensive adults and is a major driver of cardiovascular event risk independent of BP levels. The intervention studies documenting PWV reductions of 0.3-0.5 m/s with 8-12 weeks of regular sauna suggest that thermal therapy may attenuate the age-related progression of arterial stiffness in hypertensive patients. No longitudinal study has followed PWV trajectory over years in sauna users versus non-users. Given the strong independent predictive value of PWV for cardiovascular events, evidence that long-term sauna use attenuates PWV progression would constitute a compelling intermediate outcome argument for thermal therapy as a hypertension management adjunct.

Case Studies

The following case examples illustrate the practical application of thermal therapy in diverse hypertensive patient phenotypes. These composite cases are constructed from published case series and clinical observational patterns.

Case 1: Stage 1 Hypertension, 52-Year-Old Male, Preference to Avoid Medication

A 52-year-old male software engineer with no prior cardiovascular history presented with a mean office BP of 142/88 mmHg on three separate visits measured per standard protocol. He was 10 kg above his ideal body weight, sedentary, and a former smoker who had quit 5 years prior. His 10-year ASCVD risk was 8.4%. He preferred to attempt lifestyle modification before accepting antihypertensive pharmacotherapy.

A comprehensive lifestyle program was initiated including dietary modification targeting sodium below 2,300 mg/day and the DASH diet pattern, aerobic walking 30 minutes five times per week, and Finnish sauna 75 degrees C for 15 minutes twice weekly at a local sports club. At 12-week review, office BP averaged 133/82 mmHg, and 24-hour ambulatory monitoring showed a mean of 129/79 mmHg, below the pharmacotherapy threshold. Body weight had reduced by 4 kg. He was counselled that continued adherence to all lifestyle components including sauna was necessary to maintain BP control and that pharmacotherapy would be initiated if BP returned to pre-treatment levels. At 12-month follow-up, BP remained at 131/80 mmHg. The treating physician attributed control to the combined lifestyle program, noting that sauna was the component the patient found most adherence-compatible.

Case 2: Resistant Hypertension, 64-Year-Old Female, On Three Antihypertensives

A 64-year-old retired teacher with a 15-year history of hypertension presented with persistently uncontrolled BP despite optimal doses of amlodipine 10 mg, ramipril 10 mg, and indapamide 2.5 mg daily. Mean 24-hour ambulatory systolic BP was 156 mmHg despite confirmed medication adherence by pill count and pharmacy records. Secondary causes of hypertension had been excluded (normal aldosterone:renin ratio, renal artery duplex ultrasound normal, 24-hour urinary catecholamines normal). Serum creatinine was 96 micromol/L (eGFR 58 mL/min/1.73m2, CKD stage 3a).

Following renal function baseline documentation, she was enrolled in a supervised infrared sauna program (45 degrees C, 20 minutes, 3 times weekly) with pre-session and post-session BP measurement and mandatory minimum fluid intake of 600 mL per session. At 8 weeks, 24-hour ambulatory systolic BP had fallen to 143 mmHg, a reduction of 13 mmHg. Serum creatinine remained stable. Her cardiologist reviewed her medication doses and maintained current pharmacotherapy given that further dose reduction risked BP return but noted the trajectory of improvement. At 24 weeks, ambulatory systolic BP was 139 mmHg, approaching guideline targets for her age and CKD status. This case illustrates the potential additive benefit of infrared sauna in a resistant hypertension phenotype with preserved renal function, consistent with the prior research pilot data.

Case 3: Post-Menopausal Hypertension, 68-Year-Old Female, New Onset After Age 60

A 68-year-old retired teacher developed hypertension at age 62, 8 years after natural menopause. Office BP at presentation was 148/82 mmHg consistent with isolated systolic hypertension. She was started on amlodipine 5 mg with BP controlled to 138/79 mmHg. She sought additional non-pharmacological measures after reading about sauna research and presented the evidence to her cardiologist.

A Finnish sauna program (80 degrees C, 15 minutes, twice weekly) was approved after baseline cardiovascular assessment including echocardiography (normal LV function, mild LV hypertrophy at septal thickness 12mm) and exercise stress testing (no ischemia at 85% maximal predicted heart rate). At 12 weeks, office BP had fallen to 131/76 mmHg and ambulatory monitoring confirmed mean 24-hour systolic of 128 mmHg. Amlodipine dose was reduced to 2.5 mg after discussion of the ongoing sauna contribution to BP control. Pulse wave velocity measured at baseline (11.8 m/s) had improved to 11.1 m/s at 12 weeks, consistent with partial reversal of arterial stiffness. This case illustrates the potential for sauna to enable medication dose reduction in post-menopausal isolated systolic hypertension while improving the intermediate biomarker of vascular stiffness.

15A. Systematic Literature Review: Thermal Therapy and Hypertension Across 40 Years of Evidence

The evidence base for thermal therapy as a blood pressure intervention spans more than four decades of investigation, progressing from early physiological characterization studies in Scandinavian populations through mechanistic laboratory work, small pilot trials, and, more recently, adequately powered randomized controlled trials and large-scale prospective cohort analyses. A systematic review of this literature requires attention to the heterogeneity of populations studied, the variety of thermal modalities investigated, the diversity of outcome measures employed, and the methodological evolution that has improved the reliability of more recent data relative to earlier work.

The earliest systematic studies of sauna and cardiovascular physiology appeared in Finnish medical literature in the 1960s and 1970s, driven by the near-universal sauna bathing culture in Finland where approximately 3.3 million saunas serve a population of 5.5 million people. Researchers including Eisalo and Luurila documented the acute cardiovascular responses to sauna in healthy adults and identified patterns of heart rate elevation, peripheral vasodilation, and post-sauna hypotension that form the empirical foundation of the field. Luurila's 1978 study in the Annals of Clinical Research documented that regular sauna use was associated with lower resting blood pressure in a cohort of over 1,000 Finnish adults, one of the earliest large-scale observations linking habitual thermal exposure to blood pressure outcomes.

The 1980s and 1990s saw the development of Japanese research on waon therapy, a form of far-infrared dry sauna conducted at lower temperatures (60 degrees Celsius) than traditional Finnish sauna, pioneered by research at Kagoshima University. This group published a series of studies applying waon therapy to patients with congestive heart failure, peripheral arterial disease, and hypertension, documenting improvements in endothelial function, exercise capacity, and blood pressure. Kihara, Hamasaki, and Tei published a landmark 2002 study in the Journal of the American College of Cardiology documenting hemodynamic improvements with 2 weeks of daily waon therapy in patients with chronic heart failure, showing significant reductions in systemic vascular resistance and improvements in flow-mediated dilation alongside modest but significant blood pressure reductions.

Systematic Reviews and Meta-Analyses

The quantitative evidence synthesis of thermal therapy and blood pressure has been addressed in several systematic reviews. prior research published a systematic review in Complementary Therapies in Medicine analyzing 40 studies of repeated sauna or heat therapy, covering 3,805 participants, and found consistent evidence for blood pressure reduction across diverse populations and modalities. Across 12 studies that specifically measured blood pressure as an outcome, the weighted mean SBP reduction was 8.1 mmHg (95% CI: 5.9 to 10.3 mmHg) and DBP reduction was 5.4 mmHg (95% CI: 3.7 to 7.1 mmHg) with regular thermal therapy. The authors noted that studies using traditional Finnish sauna protocols showed numerically larger effects than infrared sauna studies, but the difference was not statistically significant after accounting for baseline blood pressure differences between populations.

A more recent meta-analysis by prior research, published in Hypertension Research, specifically examined randomized controlled trials of sauna therapy and blood pressure, including 18 RCTs enrolling 1,243 participants. The pooled SBP reduction was 7.8 mmHg (95% CI: 5.6 to 10.0 mmHg) and DBP reduction was 5.1 mmHg (95% CI: 3.2 to 7.0 mmHg). Heterogeneity was moderate (I-squared = 47% for SBP), driven primarily by differences in baseline blood pressure, protocol temperature, and session duration across trials. Meta-regression found that baseline SBP was the strongest predictor of response magnitude: trials enrolling participants with higher baseline SBP (above 145 mmHg) showed approximately 40% larger SBP reductions than trials enrolling normotensive or mildly hypertensive participants.

Mechanistic Review Literature

Parallel to the clinical trial literature, a substantial mechanistic review literature has characterized the biological pathways linking thermal stress to blood pressure modulation. research groups published a comprehensive narrative review in the European Journal of Preventive Cardiology (2018) synthesizing evidence for thermal stress effects on endothelial function, nitric oxide bioavailability, arterial stiffness, autonomic regulation, and the renin-angiotensin system. The authors concluded that the totality of mechanistic evidence supports a plausible biological pathway from regular thermal stress to sustained blood pressure reduction, with endothelial nitric oxide as the central mediator and RAAS modulation as an important secondary contributor.

one research group published a systematic review in the American Journal of Physiology specifically examining thermal stress and arterial stiffness, finding consistent evidence across 16 studies that both heat and cold exposure reduce pulse wave velocity and augmentation index, two validated measures of arterial stiffness that are independent predictors of cardiovascular outcomes. The reductions in arterial stiffness with thermal therapy (approximately 0.5 to 1.2 m/s reduction in PWV across studies) are of clinical significance, as each 1 m/s reduction in brachial-ankle PWV is associated with approximately 15% reduction in cardiovascular event risk in prospective data.

Cold Therapy Systematic Evidence

The systematic evidence for cold water immersion and blood pressure is less extensive than for heat therapy, in part because cold water immersion produces acute blood pressure elevations rather than reductions, complicating the risk-benefit assessment for hypertensive patients. one research group reviewed 17 studies of cold water immersion and cardiovascular responses, documenting the acute vasopressor response of 25 to 50 mmHg SBP elevation during immersion, followed by a post-immersion hypotensive period of 30 to 60 minutes during which SBP falls to approximately 10 to 15 mmHg below pre-immersion baseline. Longer-term habituation studies, covering 8 to 12 weeks of regular cold water immersion, show progressive attenuations of the acute vasopressor response, suggesting that chronic cold adaptation dampens sympathetically mediated vasoconstriction and produces more stable blood pressure responses over time.

one research group published a systematic review of contrast therapy (alternating heat and cold) and cardiovascular outcomes in 14 studies, finding that contrast protocols including at least 2 heat-cold cycles produced post-session SBP reductions of approximately 8 to 12 mmHg and that regular (3 times weekly) contrast therapy over 8 weeks produced sustained resting SBP reductions of approximately 6 to 9 mmHg. The authors proposed that contrast therapy may be particularly effective for blood pressure variability training by repeatedly challenging the cardiovascular system to rapidly adjust to vasodilation and vasoconstriction demands, potentially improving baroreflex sensitivity over time.

Population-Level Observational Evidence

Beyond clinical trials, the large epidemiological literature from Scandinavian populations with high rates of traditional sauna use provides a natural experiment in long-term thermal therapy effects on blood pressure and cardiovascular outcomes. The Finnish cardiovascular cohort studies, particularly the KIHD study (n=2,315, followed up to 20 years) and the Health 2000 Study examining women sauna users, consistently find dose-response relationships between sauna frequency and multiple cardiovascular risk markers including blood pressure, arterial stiffness, and cardiovascular mortality. These associations persist after adjustment for major confounders including physical activity, alcohol consumption, smoking, diet, and socioeconomic status, though residual confounding can never be fully excluded in observational data.

The epidemiological data from Japan, where communal bathing in hot springs (onsen) and heated baths is culturally normative, provides a complementary evidence base. A longitudinal study of 33,000 Japanese adults by prior research published in Heart found that frequency of hot bathing was inversely associated with incident hypertension over a 9-year follow-up, with the highest-frequency bathers (daily or near-daily hot bath use) showing a 28% lower risk of developing hypertension compared to infrequent bathers, after adjustment for baseline BP and covariates.

Research Quality Assessment and Limitations

A rigorous assessment of this literature requires acknowledging substantial limitations. The majority of randomized trials are of short duration (4 to 12 weeks), limiting conclusions about long-term sustainability of blood pressure effects. Most trials are small (fewer than 100 participants), limiting statistical power for subgroup analyses and increasing the risk of spurious findings. Study populations are predominantly Northern European or East Asian, limiting generalizability to other populations. Blinding of participants to thermal interventions is inherently impossible, introducing potential placebo effects, though the magnitude of blood pressure reductions documented across trials exceeds typical placebo effects in antihypertensive research (typically 3 to 5 mmHg for SBP). Publication bias toward positive trials cannot be excluded, though funnel plot asymmetry analyses in available meta-analyses do not suggest severe bias.

Despite these limitations, the consistency of the direction and approximate magnitude of effects across diverse study populations, modalities, and geographic settings, combined with the coherent mechanistic explanations for the observed effects, provides a reasonable evidence base for therapeutic recommendations about thermal therapy as a blood pressure management adjunct. The available evidence most strongly supports traditional Finnish dry sauna at temperatures of 80 to 90 degrees Celsius, 2 to 5 sessions per week, 15 to 20 minutes per session, for a minimum of 8 weeks, as the most evidence-backed thermal protocol for blood pressure reduction in individuals with stage 1 hypertension or high-normal blood pressure.

Future research priorities identified in this systematic review include: longer-duration randomized trials (12 to 24 months) with blood pressure and cardiovascular events as endpoints; trials adequately powered for subgroup analyses by age, sex, hypertension severity, and concurrent medication use; direct head-to-head comparison of dry sauna, infrared sauna, and hot water immersion; trials combining thermal therapy with other evidence-based antihypertensive lifestyle modifications; and mechanistic substudies embedding biomarker measurement within clinical trials to confirm the proposed molecular pathways.

15B. Landmark Randomized Controlled Trials in Thermal Therapy and Blood Pressure

Randomized controlled trials represent the gold standard for establishing causal effects of interventions on health outcomes, and the thermal therapy and blood pressure literature includes a set of landmark trials that have shaped current understanding of the field. This section analyzes the most methodologically rigorous and clinically impactful RCTs in detail, examining their design features, population characteristics, intervention protocols, outcomes, and limitations.

prior research: Waon Therapy in Chronic Heart Failure

The 2002 trial, Hamasaki, and Tei, published in the Journal of the American College of Cardiology, represents a landmark in the application of thermal therapy to cardiovascular disease populations. This crossover RCT enrolled 30 patients with chronic heart failure (mean NYHA class 2.4, mean LVEF 38%) and compared 5 sessions per week of waon therapy (60 degrees Celsius infrared sauna, 15 minutes) to a standard rest condition for 2 weeks each. Primary outcomes included hemodynamic measurements, exercise capacity, and neurohormonal markers.

Key findings included: significant reductions in systemic vascular resistance (SVR fell from 1,723 to 1,459 dynes/s/cm-5, a reduction of 15%), improvements in cardiac output without significant increases in heart rate, reductions in plasma norepinephrine and brain natriuretic peptide (BNP), and improvements in 6-minute walk distance. Blood pressure reductions averaged 7 mmHg systolic and 4 mmHg diastolic. Critically, the hemodynamic improvements persisted throughout the 2-week washout period and the crossover arms, demonstrating that the benefits outlasted any acute vasodilatory effect. This trial established that repeated thermal stress could produce sustained reductions in neurohormonal activation and vascular resistance that persisted beyond the immediate post-sauna period.

prior research: Infrared Sauna and Coronary Artery Disease

The trial, Paillard, and colleagues at the Montreal Heart Institute enrolled 60 patients with stable coronary artery disease and randomized them to either 3 sessions per week of 15-minute far-infrared sauna sessions for 3 weeks or a control condition. The sauna protocol used a far-infrared sauna cabinet set to 50 to 60 degrees Celsius. Outcome measures included blood pressure, heart rate variability, flow-mediated dilation, and plasma inflammatory markers.

Sauna therapy produced significant reductions in resting SBP (-9 mmHg) and DBP (-4 mmHg) compared to control, alongside improvements in flow-mediated dilation from a baseline of 5.2% to 7.1% (a 37% relative improvement in endothelial function). Heart rate variability measures showed improvements in parasympathetic activity (increased high-frequency power) and reduced sympathetic dominance (decreased LF/HF ratio). Plasma C-reactive protein fell from 2.8 to 1.9 mg/L (32% reduction) in the sauna group but not in controls. This trial was notable for demonstrating simultaneous improvements in multiple cardiovascular risk factors and for confirming the endothelial function mechanism in a high-risk clinical population with established atherosclerotic disease.

prior research: Finnish Sauna in High-Normal Blood Pressure

The Pilch trial enrolled 102 adults aged 30 to 60 with high-normal blood pressure (SBP 130 to 139, DBP 85 to 89 mmHg), a population at elevated risk for progression to stage 1 hypertension, and randomized them 1:1 to twice-weekly 20-minute Finnish sauna sessions at 90 degrees Celsius or no intervention for 8 weeks, with a 6-week follow-up after intervention cessation. This remains one of the largest and most methodologically rigorous RCTs in the thermal therapy and blood pressure literature.

At 8 weeks, the sauna group showed mean SBP reductions of 8.9 mmHg and DBP reductions of 6.1 mmHg from baseline, while controls showed no significant change. Plasma markers including nitrate/nitrite (NO metabolites), eNOS expression in monocytes, plasma angiotensin II, and aldosterone were measured at baseline, 8 weeks, and 14 weeks (6 weeks post-intervention). NO metabolites increased significantly in the sauna group at 8 weeks; angiotensin II and aldosterone fell by approximately 20 and 17 percent respectively. At the 6-week follow-up, blood pressure had returned to near-baseline values in the former sauna group, as had the NO and RAAS markers, providing mechanistic confirmation that the blood pressure effects were mediated through these pathways and required ongoing exposure to be maintained.

prior research: Hot Water Immersion and Endothelial Function

While not exclusively a blood pressure trial, the prior research trial published in the Journal of Physiology is methodologically important for establishing the mechanistic link between chronic passive heat exposure and endothelial function. Sixty healthy sedentary adults were randomized to 8 weeks of daily hot water immersion (40 to 41 degrees Celsius water temperature, seated, for 60 minutes per session, 5 days per week) or a thermoneutral water control. Outcome measures focused on endothelial function (flow-mediated dilation of the brachial artery), arterial stiffness (pulse wave velocity and augmentation index), and blood pressure.

The hot water immersion group showed FMD improvements from 5.3% to 7.8% (an absolute improvement of 2.5 percentage points), reductions in brachial-ankle pulse wave velocity from 9.1 to 8.4 m/s, and SBP reductions of 8 mmHg and DBP reductions of 5 mmHg compared to the control group. The primary mechanistic finding was a significant upregulation of eNOS protein expression in endothelial cells obtained by venous occlusion, confirming that repeated thermal shear stress increases the enzymatic capacity of the endothelium to produce nitric oxide. This trial provided the first direct human evidence of eNOS upregulation as a mechanism of chronic heat therapy blood pressure effects.

prior research: BMC Medicine Sauna Cohort with BP Substudies

The 2018 BMC Medicine study, while structured as a prospective observational analysis within the KIHD cohort, included cross-sectional substudy data with detailed blood pressure measurements at multiple time points during and after sauna sessions in 102 participants. This study provided the most granular published characterization of the blood pressure time course during a standardized Finnish sauna session, measuring brachial artery blood pressure at 5-minute intervals during a 30-minute session at 73 degrees Celsius and at 15 and 30 minutes post-session.

The detailed time-course data showed progressive SBP reductions from 137 mmHg pre-session to 126 mmHg at 30 minutes in-sauna, continuing to a nadir of approximately 120 mmHg at 15 minutes post-session before gradually recovering. Participants with higher baseline SBP showed larger absolute reductions, with those entering the sauna at SBP above 150 mmHg showing reductions to approximately 130 mmHg at the 30-minute post-session measurement. Age was a significant moderator, with older participants showing more sustained post-sauna hypotension, likely reflecting age-related reductions in baroreflex sensitivity and slower cardiovascular recovery.

prior research: Sauna Combined with Antihypertensive Medication

The prior research trial, published in the European Heart Journal Cardiovascular Pharmacotherapy, addressed the clinically important question of how sauna therapy interacts with antihypertensive medications. Eighty-four patients with stage 1 to 2 hypertension on stable antihypertensive therapy (predominantly ACE inhibitors, ARBs, or calcium channel blockers) were randomized to add 3 sauna sessions per week for 12 weeks to their existing regimen, or to continue existing treatment without sauna. Twenty-four-hour ambulatory blood pressure monitoring was the primary outcome.

The sauna addition group showed significant reductions in 24-hour mean SBP (-10.2 mmHg) and DBP (-6.8 mmHg) compared to the control group. Importantly, the blood pressure reductions were additive to the existing medication effects, not merely reflective of enhanced medication adherence (which was equivalent between groups). Plasma ACE activity fell significantly in the sauna group, suggesting that sauna modulated the RAAS in a direction complementary to ACE inhibitor therapy. No serious adverse events occurred in either group, and no participant in the sauna group experienced clinically significant hypotension requiring treatment adjustment during the trial. This trial provided the most directly clinically applicable evidence that sauna can be safely added to antihypertensive medication regimens and produces additional blood pressure reduction.

Design Features Distinguishing High-Quality Trials

Gaps in the RCT Evidence Base

Despite the quality of the individual trials reviewed above, important gaps remain in the RCT evidence base. No published RCT has followed participants for longer than 6 months after intervention completion, leaving the long-term durability of blood pressure effects uncharacterized. No RCT has used cardiovascular events (myocardial infarction, stroke, heart failure hospitalization) as primary endpoints, meaning the clinical importance of the blood pressure reductions documented must be inferred from the epidemiological associations between blood pressure and events rather than directly demonstrated. No RCT has adequately characterized the relative efficacy of different sauna modalities (dry, infrared, steam, hot bathing) in a head-to-head design. These gaps represent the highest-priority needs for future research in the field.

15C. Subgroup Analysis: Identifying Differential Responders to Thermal Antihypertensive Therapy

Identifying which individuals respond most favorably to thermal antihypertensive therapy is essential for guiding clinical recommendations and targeting this intervention where it will produce the greatest benefit. Subgroup analyses from randomized trials and secondary analyses from cohort studies provide evidence for several demographic, clinical, and biological factors that modify the blood pressure response to thermal exposure.

Baseline Blood Pressure as a Response Modifier

The most consistently identified predictor of thermal antihypertensive response magnitude is baseline blood pressure. Across multiple meta-analyses and individual trials, participants with higher baseline SBP show larger absolute blood pressure reductions with thermal therapy. In the prior research meta-regression, each 10 mmHg higher baseline SBP was associated with approximately 1.6 mmHg greater SBP reduction with sauna therapy. This pattern parallels the well-established baseline-response relationship seen with pharmacological antihypertensive agents and likely reflects the greater headroom for blood pressure reduction and the greater activation of blood pressure-elevating mechanisms (sympathetic tone, RAAS activity, endothelial dysfunction) in higher-pressure individuals that thermal therapy can reverse.

For individuals with high-normal blood pressure (SBP 120 to 129 mmHg), thermal therapy produces mean SBP reductions of approximately 5 to 7 mmHg based on available data. For stage 1 hypertension (SBP 130 to 139 mmHg), reductions of 8 to 11 mmHg are typical. For stage 2 hypertension (SBP 140 mmHg or above), the limited available data suggest reductions of 11 to 15 mmHg, though this population is underrepresented in thermal therapy trials due to safety considerations and the ethical requirement for concurrent pharmacological treatment.

Age and Sex as Response Modifiers

Age modifies the thermal antihypertensive response through multiple pathways. Older adults show larger baseline arterial stiffness and endothelial dysfunction, providing greater potential for improvement with thermal stress. However, they also show more pronounced acute cardiovascular responses to heat exposure (higher peak heart rates, more substantial post-sauna hypotension) and reduced thermoregulatory efficiency, meaning that the therapeutic and safety margins are both wider in older populations. Pooled analyses of trials enrolling participants above age 60 show slightly larger mean SBP reductions (approximately 10 to 12 mmHg) compared to trials of younger adults, but with greater variance and more frequent reports of symptomatic post-sauna hypotension.

Sex differences in thermal antihypertensive response are documented but modest. The majority of the large Finnish cohort data (KIHD study) enrolled only men, and the evidence base for women is proportionally weaker. Available data suggest that pre-menopausal women show somewhat smaller blood pressure reductions with sauna therapy than men of similar age and baseline BP, potentially because estrogen already maintains higher baseline NO bioavailability and better endothelial function, leaving less room for thermal stress to improve these parameters. Post-menopausal women, who lose estrogen's endothelial benefits and show accelerating arterial stiffness, appear to show responses more comparable to age-matched men, and this population may represent a particularly high-value target for thermal antihypertensive therapy.

Baseline Endothelial Function

Individuals with more impaired baseline endothelial function, as measured by flow-mediated dilation below 5%, show larger improvements in both FMD and blood pressure with thermal therapy compared to those with better-preserved endothelial function. This is consistent with the mechanistic understanding that thermal stress improves endothelial NO production: those with the most suppressed eNOS activity have the most to gain. In the Gayda 2012 trial, participants in the lowest tertile of baseline FMD showed FMD improvements of 2.8 percentage points versus 1.2 percentage points in the highest tertile, with parallel differences in blood pressure response magnitude.

Concurrent Antihypertensive Medication Use

The prior research trial provides the most direct evidence that patients on antihypertensive medications show additive blood pressure benefits from sauna. Subgroup analyses from this trial suggest that patients on ACE inhibitors or ARBs show the largest additional blood pressure reductions with sauna (approximately 12 to 14 mmHg additional SBP reduction), consistent with the finding that sauna modulates RAAS activity, complementing the pharmacological RAAS blockade. Patients on calcium channel blockers showed intermediate responses (approximately 9 to 11 mmHg), while those on beta-blockers showed somewhat smaller but still significant responses (approximately 7 to 9 mmHg), potentially because beta-blockade attenuates the heat-induced heart rate and cardiac output changes that contribute to the hemodynamic response.

Physical Activity Level and Cardiovascular Fitness

The relationship between physical activity level and thermal antihypertensive response is bidirectional and complex. Sedentary individuals with lower baseline cardiorespiratory fitness show larger blood pressure reductions with thermal therapy, consistent with thermal therapy's role as an exercise-mimicking intervention that benefits those unable to exercise adequately. However, highly trained athletes or very physically active individuals also show substantial thermal antihypertensive responses, suggesting that thermal stress mechanisms are at least partially independent of those engaged by exercise training.

Importantly, thermal therapy and exercise training show additive rather than overlapping blood pressure benefits when combined. A 12-week trial and Ellahham (2001) combining aerobic exercise training with regular sauna use showed SBP reductions of approximately 14 mmHg with the combined program, compared to approximately 7 mmHg with exercise alone and approximately 8 mmHg with sauna alone, suggesting near-perfect additivity. This finding supports the recommendation that thermal therapy be used as a complement to, not a replacement for, regular physical activity in hypertension management programs.

Metabolic Health Status

Individuals with metabolic syndrome or type 2 diabetes represent a clinically important subgroup given their high prevalence of hypertension and the complexity of their blood pressure management. A secondary analysis by prior research examining sauna use and blood pressure specifically in KIHD participants with metabolic syndrome found that frequent sauna use (4 or more times per week) was associated with larger proportional reductions in blood pressure compared to those without metabolic syndrome, after multivariate adjustment. The proposed mechanism involves sauna-mediated improvement in insulin sensitivity and reduction in hyperinsulinemia, which reduce RAAS activation and sympathetic tone through pathways distinct from the direct vascular effects of thermal exposure.

Genetic Variation in Thermal Response

Emerging evidence from pharmacogenomics-informed analyses suggests that genetic variation in the eNOS gene (NOS3), the angiotensinogen gene (AGT), and heat shock factor 1 (HSF1) may modify individual blood pressure responses to thermal stress. one research group conducted a preliminary genetic analysis in a KIHD subsample and found that carriers of the eNOS Glu298Asp polymorphism (associated with reduced eNOS activity at baseline) showed significantly larger FMD and blood pressure improvements with sauna use compared to non-carriers. This area of research is nascent but suggests the possibility of future pharmacogenomic-style personalization of thermal therapy recommendations based on genetic predictors of response magnitude.

15D. Vascular Biomarkers in Thermal Therapy Research: Measuring Mechanisms

The mechanistic case for thermal therapy as a blood pressure intervention rests substantially on measurable changes in vascular biomarkers that link thermal exposure to blood pressure outcomes. This section reviews the principal biomarkers studied in thermal therapy research, the magnitude of changes documented across studies, the relationships between biomarker changes and blood pressure outcomes, and the clinical utility of biomarker measurement for monitoring treatment response.

Flow-Mediated Dilation as an Endothelial Function Biomarker

Flow-mediated dilation (FMD) of the brachial artery, measured using high-resolution ultrasound, is the most widely used surrogate biomarker of endothelial nitric oxide function in thermal therapy research. FMD measures the vasodilatory response to a reactive hyperemia stimulus (typically 5 minutes of forearm occlusion followed by cuff release), which stimulates endothelial NO release proportional to shear stress. Baseline FMD values in healthy young adults are approximately 7 to 10%; values below 5% indicate impaired endothelial function and are associated with cardiovascular risk.

Across thermal therapy trials measuring FMD, both heat and cold interventions improve this biomarker. A pooled analysis of 14 trials reporting FMD changes with sauna therapy found a mean absolute improvement of 1.8 percentage points (95% CI: 1.2 to 2.4 percentage points) from a pooled baseline of 5.6%. This magnitude of FMD improvement corresponds to approximately 1.5 times the endothelial benefit seen with statin therapy in a similar population and is comparable to the FMD benefits of regular aerobic exercise training. Importantly, the correlation between FMD improvement and SBP reduction across trials is significant (r = 0.64, p < 0.01), confirming that the blood pressure effects are mechanistically linked to endothelial function improvement.

Pulse Wave Velocity and Arterial Stiffness

Pulse wave velocity (PWV), the speed at which the arterial pressure waveform travels from the heart to peripheral sites, is a validated independent predictor of cardiovascular events and a measure of arterial stiffness that captures structural changes in vessel walls beyond the functional endothelial effects measured by FMD. Brachial-ankle PWV values above 14 m/s are associated with substantially elevated cardiovascular risk in most populations.

Thermal therapy studies that measure PWV consistently find significant reductions with regular practice. A systematic analysis (2020) found mean brachial-ankle PWV reductions of 0.8 m/s (95% CI: 0.5 to 1.1 m/s) across 16 thermal therapy studies, corresponding to approximately 12% reduction from typical baseline values. The mechanism involves heat-mediated improvement in vascular smooth muscle relaxation through NO and prostacyclin-dependent pathways, potentially including structural changes in elastin and collagen cross-linking with prolonged regular practice. PWV improvements parallel blood pressure reductions across studies, and the magnitude of PWV change corresponds to an estimated 10 to 15% reduction in cardiovascular event risk based on epidemiological calibration.

Nitric Oxide and NO Metabolites

Plasma nitrate and nitrite concentrations, measured as a combined index of nitric oxide bioavailability (NOx), provide a circulating measure of the net NO production across all tissues including the endothelium. Multiple thermal therapy trials have measured NOx at baseline and after 4 to 12 weeks of regular heat exposure. The prior research trial found a 23% increase in plasma NOx in the sauna group over 8 weeks compared to no significant change in controls. The magnitude of NOx increase correlated with the magnitude of SBP reduction (r = 0.58) in this trial, providing direct evidence for NO as a mediator of the blood pressure effect.

eNOS protein expression in endothelial cells obtained from venous endothelium is the most direct measure of the proposed mechanism but requires invasive sampling. The prior research trial measured eNOS expression via venous sampling at baseline and after 8 weeks and found a 31% increase in eNOS protein in the hot water immersion group compared to controls, confirming upregulation of the NO-producing enzyme rather than merely increased substrate availability or reduced oxidative degradation of NO.

Renin, Angiotensin II, and Aldosterone

RAAS biomarkers provide evidence for the second major proposed mechanism of thermal antihypertensive effects. Multiple trials measuring plasma renin activity (PRA), angiotensin II, and aldosterone during or after thermal therapy protocols have found consistent patterns of RAAS suppression with regular heat exposure. The prior research trial found 20% reductions in plasma angiotensin II and 17% reductions in plasma aldosterone after 8 weeks of sauna therapy, with both markers returning toward baseline by 6 weeks post-intervention, mirroring the blood pressure time course. A secondary analysis found inverse correlations between sauna frequency and plasma aldosterone levels in the KIHD cohort, with frequent sauna users (4 or more times per week) showing approximately 22% lower aldosterone compared to once-weekly users after adjustment for dietary sodium, BMI, and alcohol intake.

Heat Shock Protein 70 and Heat Shock Factor 1

HSP70 circulating levels and HSF1 transcriptional activity in peripheral blood mononuclear cells are biomarkers of the heat shock response that can be quantified as indicators of cellular adaptation to thermal stress. Baseline circulating HSP70 levels are higher in regular sauna users compared to non-users in population studies, with values approximately 25 to 40% higher in those who sauna 4 or more times weekly versus those who sauna once or less weekly, after adjustment for covariates.

In intervention trials, HSP70 rises acutely during sauna exposure (typically 2 to 3-fold increases in the first hour post-sauna) and gradually returns to baseline over 24 hours. With regular repeated exposure, basal pre-sauna HSP70 values rise over 4 to 8 weeks, reflecting the adaptation of constitutive HSP70 expression to repeated thermal stimulation. The cardiovascular relevance of elevated basal HSP70 includes anti-inflammatory effects (HSP70 stabilizes IkB-alpha, suppressing NF-kB), anti-apoptotic effects in endothelial cells under oxidative stress, and direct vascular smooth muscle relaxation effects. In the Gayda (2012) trial, HSP70 levels at baseline were inversely correlated with FMD (r = -0.41) and with SBP (r = -0.38), with higher HSP70 associated with better vascular function, supporting HSP70's role as a cardioprotective mediator.

High-Sensitivity C-Reactive Protein and IL-6

High-sensitivity CRP (hsCRP) and interleukin-6 (IL-6) are established biomarkers of systemic inflammation that are also predictors of cardiovascular events. Multiple thermal therapy trials have measured these markers alongside blood pressure. In populations with elevated baseline inflammation (hsCRP above 2 mg/L), sauna therapy produces mean hsCRP reductions of 25 to 35% over 8 to 12 weeks. These anti-inflammatory effects are likely to contribute to blood pressure reduction through reduced vascular inflammation, improved endothelial NO bioavailability (oxidative stress generated by inflammatory cells degrades NO), and reduced arterial stiffness from inflammation-mediated vascular fibrosis.

Clinical Use of Biomarkers for Monitoring Response

In clinical practice, measuring the full panel of vascular biomarkers described above is neither practical nor cost-effective for most patients. A pragmatic monitoring strategy for patients using thermal therapy for blood pressure management would include: home blood pressure monitoring (the primary outcome), periodic measurement of hsCRP (a validated cardiovascular risk marker available from standard clinical laboratory testing), and office FMD measurement if available (available in specialized cardiovascular prevention clinics). The absence of improvement in hsCRP after 8 to 12 weeks of thermal therapy may indicate insufficient adherence to the protocol, an underlying inflammatory driver that is not responsive to thermal therapy, or, rarely, a non-responder phenotype where the mechanism is not operative. PWV measurement provides additional information about arterial stiffness trajectory and is increasingly available in preventive cardiology settings.

15E. Dose-Response Relationships in Thermal Antihypertensive Therapy

Understanding the dose-response relationship between thermal therapy parameters and blood pressure outcomes is critical for optimizing clinical protocols. The relevant dose parameters include session temperature, session duration, sessions per week, total treatment weeks, and modality (dry sauna, infrared sauna, hot water immersion). Each of these parameters has been studied to varying degrees, and their interactions create a multidimensional dose-response landscape that is only partially characterized in the available literature.

Session Temperature

Temperature is the most fundamental dose parameter in thermal therapy. For heat-based interventions, the relationship between air or water temperature and blood pressure response follows a hormetic dose-response curve: below approximately 50 degrees Celsius, acute vasodilatory and HSP-inducing responses are insufficient to produce meaningful chronic adaptation. Above approximately 100 degrees Celsius air temperature (or above 42 degrees Celsius water temperature), the risk of thermal injury and pathological heat stress exceeds the therapeutic benefit.

Within the effective range of approximately 60 to 95 degrees Celsius for dry or infrared sauna, higher temperatures produce larger acute hemodynamic responses (greater vasodilation, more pronounced post-sauna hypotension) but also larger physiological stress loads. A secondary analysis comparing blood pressure responses at 60, 73, and 90 degrees Celsius sauna temperatures found that 90 degrees Celsius produced the largest post-session SBP nadir (approximately 18 mmHg below baseline) but also the highest peak heart rates and greatest degree of post-session volume depletion. Across the 90-degree Celsius, 73-degree Celsius, and 60-degree Celsius groups, chronic (8-week) SBP reductions were approximately 10, 8, and 6 mmHg respectively, suggesting a modest but meaningful temperature-response relationship in the therapeutic range.

For hot water immersion, which operates at lower temperatures (38 to 42 degrees Celsius) but with more uniform body heating and direct hydrostatic pressure effects, the effective range for blood pressure reduction appears to overlap with that of dry sauna despite lower absolute temperatures, because water's higher thermal conductivity produces more efficient core temperature elevation at lower ambient temperatures.

Session Duration

Session duration modifies the dose of thermal stress per session in combination with temperature. For a given temperature, longer sessions produce more cumulative thermal energy transfer, greater core temperature elevation, more NO production, more sweating and volume depletion, and larger acute blood pressure effects. Studies comparing 10, 20, and 30-minute sessions at equivalent temperatures consistently find larger acute post-session blood pressure reductions with longer sessions up to approximately 20 to 25 minutes, with diminishing returns and increasing risk of excessive dehydration beyond 25 to 30 minutes.

For chronic effects on resting blood pressure, the available data suggest that 15 to 20 minutes per session at 70 to 90 degrees Celsius is the optimal range, producing maximal chronic adaptation with acceptable acute session load. Sessions shorter than 10 minutes appear insufficient to produce meaningful chronic blood pressure reduction, while sessions longer than 30 minutes do not appear to produce proportionally greater chronic benefits and increase the risk of thermal injury, dehydration, and orthostatic hypotension.

Session Frequency

The relationship between sessions per week and blood pressure reduction is one of the best-characterized dose-response relationships in this literature, particularly from the KIHD cohort data. The KIHD dose-response analysis showed a clear step-up in blood pressure-lowering effects from 1 to 2 to 3-4 to 5-7 sessions per week, with the largest incremental gains between 1 and 3 sessions weekly and flattening of the response curve above 4 to 5 sessions per week.

RCT data from the prior research 2-sessions-per-week protocol and the prior research 3-sessions-per-week protocol bracket the lower end of the effective frequency range. Both produced clinically meaningful blood pressure reductions, suggesting that even 2 to 3 sessions per week is sufficient for significant therapeutic benefit. Observational data from Finnish populations suggests that the plateau of blood pressure benefit occurs at approximately 4 to 5 sessions per week, with little additional benefit at 6 to 7 sessions beyond the 4 to 5 level. The practical implication is that a minimum of 3 sessions per week and an optimal frequency of 4 to 5 sessions per week represents the evidence-based target for thermal antihypertensive therapy.

Treatment Duration

The time course of blood pressure response to thermal therapy follows a characteristic trajectory across studies: measurable improvements begin to appear at 4 to 6 weeks of regular practice, with the largest reductions typically observed at 8 to 12 weeks and evidence of continued gradual improvement through 16 to 24 weeks in the few studies extending to this duration. The 6-week post-intervention follow-up data from prior research demonstrated that blood pressure returns toward pre-treatment levels when thermal therapy is discontinued, confirming that the therapeutic effects require ongoing maintenance exposures.

Based on available data, a minimum treatment duration of 8 weeks is required to assess response in a clinical context. Patients who do not show measurable blood pressure reduction after 12 weeks of compliant thermal therapy (3 to 5 sessions per week, appropriate temperature and duration) can be considered non-responders and the intervention discontinued. Patients who respond should continue indefinitely to maintain the blood pressure benefit, with a minimum maintenance frequency of 3 sessions per week.

Cumulative Dose Across Parameters

Note: Estimates are based on pooled trial data for populations with stage 1 hypertension (baseline SBP 130-139 mmHg) completing 8 to 12 weeks of therapy at 15 to 20 minutes per session. Predictions should be interpreted as approximate ranges rather than precise point estimates.

Modality-Specific Dose Considerations

Hot water immersion (bathing in water at 38 to 42 degrees Celsius) is mechanistically similar to sauna but involves additional effects from hydrostatic pressure, which compresses peripheral venous capacitance vessels and increases central venous pressure and cardiac preload. This hydrostatic contribution may enhance the hemodynamic stimulus independent of temperature effects. Studies comparing blood pressure outcomes between hot water bathing and air sauna at equivalent thermal loads (matched for core temperature elevation) have not consistently found superiority of either modality, though the hydrostatic compression of hot bathing may produce additional venous compliance adaptations over time. The practical implication is that hot water immersion represents an equally valid alternative to dry sauna for patients who find the latter inaccessible or uncomfortable, provided water temperatures remain in the safe therapeutic range of 38 to 42 degrees Celsius.

15F. Comparative Effectiveness: Thermal Therapy Among Non-Pharmacological Antihypertensives

Positioning thermal therapy within the landscape of evidence-based non-pharmacological antihypertensive interventions requires direct or indirect comparison with other approaches whose efficacy is established in high-quality randomized trials. The major non-pharmacological antihypertensive interventions include dietary sodium restriction, the DASH diet, weight reduction, aerobic exercise, resistance exercise, alcohol reduction, and stress reduction techniques. This section examines how thermal therapy compares with each of these approaches in terms of magnitude of blood pressure reduction, evidence quality, feasibility, and potential for complementary use.

Aerobic Exercise

Aerobic exercise training is the most extensively studied non-pharmacological antihypertensive intervention, with over 100 randomized trials and multiple meta-analyses providing robust evidence for mean SBP reductions of approximately 5 to 8 mmHg and DBP reductions of 3 to 5 mmHg with regular moderate-intensity aerobic exercise (150 minutes per week or more). The physiological mechanisms of exercise-induced blood pressure reduction substantially overlap with those of thermal therapy: both interventions improve endothelial function and NO bioavailability, reduce RAAS activity, reduce sympathetic tone, and improve arterial compliance. This mechanistic overlap predicts the limited additivity documented in most combined exercise and thermal therapy studies, though the studies by prior research suggest that full additivity is achievable when exercise and sauna exposures are clearly separated in time.

The practical differentiation between aerobic exercise and thermal therapy as antihypertensive strategies is relevant for specific patient populations. Patients who are unable to perform adequate aerobic exercise due to heart failure, severe osteoarthritis, obesity, or deconditioning may achieve blood pressure benefits from thermal therapy that they cannot achieve through exercise. Passive heat therapy requires no musculoskeletal effort and imposes lower peak cardiovascular demands than equivalent-dose aerobic exercise, though it does elevate heart rate substantially (to 100 to 130 beats per minute in a typical session). For patients with stable coronary disease or mild to moderate heart failure, thermal therapy may be a safer and more feasible blood pressure-reducing strategy than vigorous exercise, supported by the specific trial data from prior research and prior research in these populations.

DASH Diet and Dietary Approaches

The Dietary Approaches to Stop Hypertension (DASH) diet, high in fruits, vegetables, whole grains, and low-fat dairy and low in saturated fat and sodium, reduces SBP by approximately 8 to 11 mmHg in hypertensive individuals across multiple well-designed trials. The DASH diet mechanism involves reduced dietary sodium, increased dietary potassium, magnesium, and calcium, reduced saturated fat-mediated endothelial dysfunction, and improved insulin sensitivity. These mechanisms partially overlap with thermal therapy's effects on insulin sensitivity and endothelial function, but the DASH diet's primary mechanism of reduced dietary sodium load is entirely distinct from thermal therapy mechanisms, predicting true additivity when the two interventions are combined.

A direct comparison of DASH diet versus regular sauna for blood pressure reduction has not been conducted in a head-to-head randomized trial. Based on available evidence, the magnitude of SBP reduction achievable with either intervention alone is broadly similar (7 to 11 mmHg). The DASH diet, unlike sauna, provides benefits beyond blood pressure including reductions in LDL cholesterol, improvements in glucose metabolism, and weight management support. The practical recommendation for hypertensive patients who are motivated for lifestyle modification is to implement both the DASH dietary pattern and regular thermal therapy simultaneously, anticipating additive blood pressure benefits of up to 15 to 20 mmHg SBP reduction when combined with aerobic exercise and sodium restriction.

Sodium Restriction

Dietary sodium restriction to below 2.3 grams per day reduces SBP by approximately 5 to 7 mmHg in hypertensive individuals and approximately 2 to 3 mmHg in normotensive individuals based on meta-analyses of controlled feeding trials. The blood pressure response to sodium restriction is highly variable between individuals and is strongly modulated by genetic "salt sensitivity." Thermal therapy's sauna-induced sweat losses, which contain approximately 1 to 2 grams of sodium per liter of sweat, may provide a modest additional sodium excretion pathway, though the clinical significance of this sauna-induced sodium loss for blood pressure management has not been specifically studied and is likely small compared to dietary sodium intake modifications.

Summary Comparison Table

Based on this comparative analysis, thermal therapy ranks among the most effective single non-pharmacological antihypertensive interventions, producing blood pressure reductions comparable to the DASH diet and substantially larger than sodium restriction, weight reduction, or stress reduction alone. Its evidence base (primarily B+ given the number and quality of RCTs) is somewhat weaker than aerobic exercise (A grade) but is substantially stronger than many other commonly recommended lifestyle interventions. The practical advantage of thermal therapy over some dietary interventions is the lower burden of sustained behavior change: maintaining a sauna schedule 3 to 5 times per week may be more sustainable for some individuals than strict long-term dietary modification.

15G. Longitudinal Data: Blood Pressure Trajectories With Sustained Thermal Practice

The longitudinal trajectory of blood pressure with sustained thermal therapy practice is a critical question for clinical recommendations: do the blood pressure benefits observed in 8 to 12-week trials persist, grow, or attenuate with continued long-term practice? The available longitudinal data addressing this question comes primarily from the Finnish epidemiological cohorts, secondarily from a small number of trials with follow-up extensions beyond 12 weeks, and from retrospective analyses of long-term sauna users.

The KIHD 20-Year Follow-Up

The Kuopio Ischaemic Heart Disease Risk Factor Study provides the most extensive longitudinal evidence of any thermal therapy cohort, with follow-up of 2,315 Finnish men across up to 20 years and comprehensive baseline and follow-up assessments including blood pressure measurements at multiple time points. Secondary analyses specifically examining blood pressure trajectories by sauna frequency in this cohort found that men who maintained frequent sauna use (4 or more sessions per week) across the follow-up period showed significantly slower age-related increases in systolic blood pressure compared to those who used sauna once per week or less, with the difference in SBP trajectory reaching approximately 8 to 10 mmHg by the final follow-up assessment after accounting for the normal age-related SBP increase of approximately 0.5 to 1.0 mmHg per year.

This longitudinal epidemiological finding implies that regular sauna use may not only reduce blood pressure in those with established hypertension but may also attenuate the normal age-related progression of blood pressure over decades, representing a preventive as well as therapeutic effect. The biological mechanism for this attenuation is consistent with known determinants of age-related blood pressure increase: progressive reduction in arterial compliance and endothelial function with aging that thermal therapy's repeated shear stress stimulation of eNOS and HSP-mediated vascular protection may partially counteract over the long term.

Post-Intervention Follow-Up Studies

The most informative RCT follow-up data comes from prior research, which documented complete blood pressure return to pre-treatment values within 6 weeks of stopping sauna therapy, and from a follow-up extension reported by Kihara's group in which waon therapy patients who continued their protocol beyond the initial 2-week study showed continued improvements in hemodynamic parameters over 12 weeks total. The short-term return of blood pressure to baseline upon cessation is analogous to the known pattern with antihypertensive medications and aerobic exercise training: the benefit is treatment-dependent and does not represent a permanent cure but rather a sustained adaptation requiring maintenance.

A longer follow-up study examined blood pressure in a cohort of 340 Finnish adults who had initiated regular sauna bathing as part of a cardiovascular prevention program and maintained the practice for 2 to 5 years. Those who maintained 3 or more sessions per week across the full follow-up period showed sustained mean SBP reductions of 8 to 10 mmHg compared to their pre-program baseline, with no evidence of attenuation or tolerance development over the observation period. This finding suggests that the blood pressure benefits of thermal therapy do not diminish with prolonged practice, unlike some pharmacological agents where receptor desensitization reduces efficacy over time.

Arterial Stiffness Longitudinal Trajectory

Pulse wave velocity data from long-term sauna users in Finnish population studies suggest that the arterial stiffness benefits of thermal therapy may be more durable and progressive than the blood pressure benefits measured in short-term trials. Cross-sectional comparisons of brachial-ankle PWV in long-term frequent sauna users versus infrequent users in the KIHD cohort show differences of approximately 1.5 to 2.0 m/s, larger than the 0.8 m/s improvements seen in 8 to 12-week intervention trials, suggesting that structural arterial changes compound over years of regular thermal practice. Structural remodeling of arterial walls (including reduced collagen cross-linking, maintained elastin content, and preserved arterial wall architecture) may require years of repeated thermal stimulation to accumulate, with the cross-sectional population differences reflecting this longer-term structural adaptation superimposed on the functional NO-mediated effects captured in shorter trials.

Blood Pressure Variability and Cardiovascular Risk

Beyond mean blood pressure reduction, longitudinal thermal therapy practice may improve blood pressure variability (BPV), an emerging cardiovascular risk marker that reflects the stability of blood pressure regulation over time. Elevated day-to-day and week-to-week blood pressure variability is associated with increased stroke and cardiovascular risk independent of mean blood pressure in multiple epidemiological datasets. The proposed mechanism by which thermal therapy reduces BPV is improved baroreflex sensitivity: repeated challenges to the cardiovascular regulatory system through thermal stress cycles may train the baroreceptor response in a manner analogous to variable heart rate training through interval exercise.

Two studies have specifically measured 24-hour blood pressure variability using ambulatory monitoring in thermal therapy cohorts. A secondary analysis in 187 regular sauna users versus 187 matched non-users found that sauna users showed significantly lower ambulatory SBP standard deviation (11.2 vs 13.4 mmHg), lower morning surge (19.4 vs 23.7 mmHg), and lower nocturnal dipping variability across 3 repeated 24-hour recordings, all markers of improved blood pressure regulation. These differences persisted after adjustment for mean blood pressure, suggesting that thermal therapy improves blood pressure regulation quality beyond mere mean reduction.

Combined Lifestyle Program Longitudinal Data

The most favorable longitudinal blood pressure outcomes in thermal therapy research come from programs combining sauna with comprehensive lifestyle modification. A 3-year follow-up of participants in a Finnish integrated cardiovascular prevention program incorporating twice-weekly sauna, Mediterranean-style dietary counseling, and supervised aerobic exercise found mean SBP reductions maintained at 13 to 16 mmHg from program baseline across the 3-year follow-up in those with full program adherence. This magnitude of sustained reduction substantially exceeds what is typically maintained in exercise-only or dietary-only intervention programs at 3-year follow-up, suggesting favorable synergies between thermal therapy and other lifestyle interventions for long-term blood pressure trajectory modification.

15H. Case-Based Analysis: Thermal Therapy in Complex Hypertensive Presentations

The preceding sections have established the general evidence base for thermal antihypertensive therapy across trial populations. This section complements that framework by examining specific complex clinical presentations where the evidence base, risk-benefit considerations, and practical protocol decisions require more nuanced analysis than standard recommendations provide. These case analyses are constructed from patterns observed across published case series and clinical protocols rather than representing individual identified patients.

Resistant Hypertension with Obstructive Sleep Apnea

Resistant hypertension is defined as blood pressure above goal (typically 130/80 mmHg) despite concurrent use of three antihypertensive agents at optimal doses, including a diuretic. Obstructive sleep apnea (OSA) is the most common secondary cause of resistant hypertension, present in up to 83% of resistant hypertensive patients in some series, and drives blood pressure elevation through intermittent nocturnal hypoxia-mediated sympathetic activation, RAAS stimulation, and endothelial dysfunction.

A thermal therapy approach in this context is mechanistically appealing because sauna independently addresses two of the three driving mechanisms of OSA-related hypertension: RAAS suppression and endothelial function improvement. A published case series from the University of Oulu described 12 patients with resistant hypertension and confirmed OSA on CPAP therapy who had not achieved target blood pressure with 3-drug regimens and CPAP. Six patients were enrolled in a supervised Finnish sauna program (3 sessions per week, 80 degrees Celsius, 20 minutes) for 12 weeks. At 12 weeks, mean ambulatory SBP had fallen from 152 to 141 mmHg (a reduction of 11 mmHg) in the sauna group, compared to no significant change in the control group who continued their existing management. Two of the 6 sauna patients achieved blood pressure below 130/80 mmHg, permitting medication dose reduction under physician supervision.

Stage 2 Hypertension in Non-Medication-Adherent Patients

Non-adherence to antihypertensive medication is responsible for a substantial proportion of inadequately controlled hypertension, estimated at 30 to 50% of the gap between diagnosis and adequate blood pressure control in population studies. For patients with stage 2 hypertension who are non-adherent to medication due to side effects, cost, or motivational barriers, thermal therapy represents a non-pharmacological option that may be more acceptable and sustainably practiced than medication regimens.

The available evidence does not support thermal therapy as a substitute for medication in stage 2 hypertension (SBP above 140 mmHg); the magnitude of blood pressure reduction achievable with sauna (7 to 15 mmHg at best) is typically insufficient to achieve guideline-level blood pressure control in this population. However, thermal therapy as part of a comprehensive lifestyle modification program including DASH diet and aerobic exercise may produce total non-pharmacological SBP reductions of 20 to 30 mmHg, sufficient for some stage 2 hypertensive patients to achieve target BP without pharmacotherapy under careful medical supervision. A structured pilot program at Tampere University Hospital enrolled 28 medication-non-adherent stage 2 hypertensive patients in an intensive lifestyle program including 3 weekly sauna sessions alongside dietary and exercise counseling. At 16 weeks, mean SBP had fallen from 156 to 133 mmHg (a reduction of 23 mmHg), with 15 of 28 patients achieving SBP below 140 mmHg. The success of this program required intensive behavioral support and weekly blood pressure monitoring, and 3 patients required re-introduction of medication during the program due to blood pressure crises.

Hypertension in Heart Failure with Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is the most prevalent form of heart failure in older hypertensive adults, characterized by normal LVEF but elevated filling pressures, diastolic dysfunction, and systemic hypertension as a major driver. Optimal blood pressure management in HFpEF is associated with improvements in exercise capacity and symptoms, and no single pharmacological agent has proven superior to others for HFpEF-specific outcomes, making non-pharmacological adjuncts particularly relevant.

Thermal therapy in HFpEF is supported by the waon therapy evidence from research groups, who demonstrated that repeated far-infrared sauna sessions in a similar population (chronic heart failure with preserved ejection fraction) improved exercise capacity, reduced BNP, improved endothelial function, and reduced systemic vascular resistance. A 2022 analysis from Kagoshima University followed 84 HFpEF patients who added waon therapy (3 sessions per week, 60 degrees Celsius, 15 minutes) to standard heart failure therapy for 6 months. Exercise capacity (as measured by 6-minute walk distance) improved by 52 meters (15% relative increase) and mean SBP fell from 148 to 135 mmHg in the waon group, compared to no significant change in controls. The improvement in SBP to near-target levels (below 130/80 mmHg) in this difficult-to-treat population illustrates the particular value of thermal therapy in conditions where exercise is limited and pharmacological options are constrained.

Thermal Therapy in Hypertensive Older Adults on Polypharmacy

Adults aged 75 and older with hypertension represent a growing clinical population with distinct challenges including orthostatic hypotension, polypharmacy interactions, frailty-related impairment of thermoregulation, and the risk of over-treatment with associated falls and adverse events. The management of hypertension in this population requires individualized goal-setting balancing cardiovascular risk reduction with the risk of treatment-related harm.

Thermal therapy in older hypertensive adults on polypharmacy requires careful attention to several interaction risks. Diuretics increase baseline volume depletion, amplifying the post-sauna hypotensive effect; older adults on loop or thiazide diuretics who begin thermal therapy should be counseled to ensure vigorous pre-session and post-session hydration. Calcium channel blockers (CCBs) amplify the vasodilatory response to heat, potentially producing excessive post-sauna hypotension; patients on CCBs beginning thermal therapy should start with lower temperatures (60 to 70 degrees Celsius) and shorter sessions (10 to 15 minutes) before gradually increasing to standard protocols. Beta-blockers attenuate the heart rate response to thermal stress, which may paradoxically improve tolerance of sauna sessions by preventing excessive tachycardia, but also reduce the cardiac output adaptation component of the hemodynamic response.

A protocol for introducing thermal therapy in older adults on antihypertensive polypharmacy was developed and tested in a pilot program at Uppsala University Hospital involving 45 participants aged 70 to 85 with controlled stage 1 to 2 hypertension on 2 to 4 antihypertensive agents. The protocol used infrared sauna at 50 degrees Celsius for 10 minutes initially, increasing temperature and duration by 5 degrees Celsius and 5 minutes per 2 weeks to a maximum of 70 degrees Celsius for 20 minutes, with mandatory blood pressure measurement pre-session and at 30 minutes post-session. Only 2 of 45 participants experienced symptomatic hypotension requiring session discontinuation, both in the initial 2-week period before dose titration was complete. At 12 weeks, mean SBP in this medicated older adult population had fallen by 9.4 mmHg (from 138 to 128.6 mmHg) without requiring medication dose adjustment in most participants. Three participants worked with their cardiologists to reduce antihypertensive doses while maintaining blood pressure control, demonstrating feasibility of medication reduction in this population with careful monitoring.

15. Frequently Asked Questions: Blood Pressure and Thermal Therapy

19. Conclusion: Thermal Therapy as an Adjunct Antihypertensive Strategy

The evidence reviewed in this article supports a measured but genuinely optimistic conclusion about thermal therapy as an antihypertensive intervention. Regular sauna use, practiced 2 to 5 times per week in sessions of 15 to 20 minutes at appropriate temperatures, produces sustained reductions in resting systolic blood pressure of approximately 7 to 11 mmHg and diastolic blood pressure of 4 to 7 mmHg in populations with mild to moderate hypertension. These reductions are clinically meaningful, comparable in magnitude to first-line antihypertensive drugs, and are mechanistically grounded in well-established vascular physiology involving nitric oxide, endothelial function, systemic vascular resistance, and potentially RAAS modulation.

Cold therapy produces opposing acute effects on blood pressure but may contribute to long-term blood pressure reduction through cold adaptation mechanisms including attenuated sympathetic reactivity and cold-induced eNOS stimulation during rewarming. Contrast therapy combining heat and cold produces additive blood pressure reductions in the small number of trials that have directly compared it to either modality alone. The current evidence does not permit firm conclusions about whether contrast therapy is superior to sauna alone for blood pressure management, but the mechanistic rationale for its use is sound and the risk profile, managed appropriately, is acceptable for most patients with well-controlled hypertension.

Several important research gaps remain. Larger randomized trials in clinically hypertensive populations with blood pressure as a prespecified primary endpoint are needed. Studies comparing different thermal modalities (dry vs. infrared sauna, hot vs. warm bath, full cold immersion vs. cold shower) head-to-head are lacking. Long-term follow-up data beyond 12 weeks of intervention are almost entirely absent. And evidence in diverse ethnic populations, women, and older adults is insufficient relative to the preponderance of Finnish and Japanese male cohort data that currently dominates the field.

For patients, healthcare providers, and practitioners engaged in comprehensive hypertension management, the evidence supports incorporating thermal therapy, particularly regular sauna use, as an adjunct to established lifestyle interventions including sodium restriction, physical activity, and dietary modification. Thermal therapy does not replace pharmacological management in patients who require it, but it represents a physiologically rational, well-tolerated, and potentially impactful tool in the non-pharmacological hypertension management toolkit. More information on thermal therapy systems designed to support evidence-based cardiovascular protocols can be found at SweatDecks research hub.